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Abstract 
Addictive diseases such as those stemming from the use of alcohol, cocaine and opioids 
lead to serious negative consequences at both the individual and societal level. Over the last two 
decades, there has been a significant increase in opioid prescriptions and addiction.  The 
potential for addiction is related to factors that include genetics, prescriber behavior, user 
behavior and characteristics, in addition to environmental and systemic determinants.  One 
measure of the seriousness of the opioid epidemic is the number of overdose deaths.  In 2017, 
drug overdoses killed over seventy thousand Americans, and overdose deaths are projected to 
increase in the future.   Despite the risk of addiction and overdose, opioids are commonly 
prescribed to combat pain.  This paper uses cross-sectional county and state level data to 
examine the socioeconomic, demographic, and community level factors that are important in 
explaining opioid overdose deaths
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I. Introduction: Addiction, Opioids, and the Opioid Epidemic 
Understanding the opioid epidemic and developing effective policy solutions in addition to 
treatment options for opioid addiction requires an interdisciplinary approach.  The range of 
relevant literature incorporates the biological/chemical and non-biological causes of addiction, 
pain prevalence and its management, the historical events leading to the role of opioids in 
treating pain, and knowledge about the epidemic from empirical studies.  
A. Addiction and Opioids 
1. Addictive Diseases Are Costly 
Addictive diseases such as those stemming from the use of alcohol, cocaine and opioids 
lead to serious negative consequences at both the individual and societal level.  Addiction 
adversely affects an individual’s mental and physical health. In addition, the societal and 
economic costs are substantial. These diseases have been associated with an increase in other 
diseases such as hepatitis, domestic and child abuse, crime, and lost wages and employment.   
2. Addiction is a Chronic Brain Disease  
Addiction is a chronic disease of the brain that is characterized by compulsive substance 
use, impaired control, craving, and social problems. Like other chronic diseases, addiction often 
involves cycles of relapse and remission. (Dennis et al 2007, Sussman and Sussman 2011).  The 
human brain consists of billions of complex cells called neurons which are organized into 
networks.  When a neuron receives enough signals from other neurons, it sends its own signal to 
the other neurons in its network.  Some drugs interfere with this process of communication by 
mimicking the signals of natural neurons (NIDA 2018).  This inference can lead to changes in 
the structure of the brain and addiction.   
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The purpose of prescription opioids is to effectively manage pain; however, patients 
using opioids risk becoming addicted to the medication.  Just under a third of opioid 
prescriptions are estimated to be misused (Doyle 2016).    Opioid addiction is characterized by 
dependence on opioid substances.  The brain is naturally inclined to repeat actions that stimulate 
the reward system or provoke feelings of pleasure. Once a person has taken opiates, their brain 
wants to repeat the pleasurable feeling and effectively trains itself to be addicted to drugs.  On a 
neurological level, opioids attach to a neuron’s opioid receptor in the brain and block pain 
(Labonville 2017, Van Zee 2009).  Even though opioid addiction is treatable like many other 
chronic diseases, in practice, it is often untreated and stigmatized (Chandler et al 2009, Dennis et  
al 2007).  Because drug abuse changes the structure of the brain, opioid addiction is progressive 
if left untreated, resulting in a significant impact on mental and physical health (Weber 2019).  
3. Factors Affecting Addiction  
In 2011, The American Society of Addictions Medicine (ASAM) released a new 
definition of addiction which focuses on addiction as a chronic brain disorder rather than a 
behavioral problem.   Their definition states:  
Addiction is a treatable, chronic medical disease involving complex interactions among brain 
circuits, genetics, the environment, and an individual’s life experiences. People with addiction 
use substances or engage in behaviors that become compulsive and often continue despite 
harmful consequences. (ASAM 2011) 
 
  It has been suggested that genetics account for about 50% of the likelihood that 
someone will develop an addiction.  There are many other factors that determine an individual’s 
likelihood of addiction, however, having a family history of addiction significantly increases the 
risk of addiction.  Environmental factors such as family interactions and culture interact with an 
individual’s biological factors and affect the extent to which genetic factors exert their influence 
(Smith 2012).  In addition, the potential for addiction is related to factors that include individual 
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and psychological characteristics, socioeconomic status, and geographical area.  Public policy 
also plays an important role.  For example, government regulation determines both the viability 
of opioid prescriptions and accessibility of opioid addiction treatment. 
4. Types of Opioids  
The term “opioid” typically includes opiates, semi-synthetic opioids and synthetic 
opioids.  Opiates are natural substances that originate from opium that is extracted from the 
opium poppy.  Opium poppies contain more than twenty different opiates (Labonville 2017).    
Of those opiates, only four are used by the medical industry: morphine, codeine, thebaine and 
papaverine.  Morphine and codeine are two of the oldest pain medications still prescribed by 
doctors today (Elkins 2018). 
Although semi-synthetic and synthetic opioids bind to the same receptors in the brain as 
opiates, they do not occur naturally.  While synthetic opioids are entirely manufactured, semi-
synthetic opioids are a hybrid resulting from chemical modifications to opiates (Labonville 
2017).  For example, thebaine is converted into other chemicals, such as oxycodone or 
hydrocodone.  Therefore, oxycodone and hydrocodone are classified as semi-synthetic opioids.  
They are popular pain medications.  Well-known synthetic opioids include methadone, fentanyl, 
and meperidine (Elkins 2018).   
Opioids are also categorized as a narcotic. According to the Drug Enforcement 
Administration, the term “narcotic” was once used to describe any drug that relieved pain and 
caused relaxation, but is now commonly used to refer to opioids, (Elkins 2018).  However, the 
term is no longer used in medical settings due to its association with illegal drugs (Labonville 
2017).   
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5. Opioid Overdose and Tolerance  
While opioids can be used to relieve pain, opioids also affect the part of the brain that 
regulates breathing.  When someone takes high doses of opioids, it can lead to an overdose with 
the slowing or stopping of breathing and sometimes death (Elkins 2018).  Symptoms of opioid 
overdose include confusion, delirium, frequent vomiting, pinpoint pupils, the inability to wake 
up, intermittent loss of consciousness, breathing problems, respiratory arrest, and cold or bluish 
skin around the lips or under the fingernails (AAC 2019).  In 2011, the Centers for Disease 
Control and Prevention (CDC) classified overdoses from prescription painkillers as an epidemic.  
The leading cause of accidental death in the United States is due to drug overdoses. Opioids are 
the most common drugs involved in those deaths (Schiller et al 2019). 
Tolerance occurs when a higher dose of a drug is required to achieve the same 
pleasurable effect delivered by an initial smaller dose.  Drug tolerance develops in response to 
repeated use over time (NIH 2017).  A person’s tolerance to a drug changes their perspective on 
the amount of the drug that they can safely handle.  If drug tolerance declines unknowingly, drug 
users are more likely to overdose.  For example, former opioid users who have been recently 
released from prison or have recently detoxed are more likely to overdose than new opioid users 
(Kumar 2016). 
B. The Opioid Epidemic  
1. Chronic Pain and the Role of Opioids in Pain Treatment 
Records of opium growth date back to 3400 B.C. when the Sumerians cultivated the 
opium poppy in lower Mesopotamia. The Sumerians referred to it as Hul Gil, the "joy plant."  
The use of opium spread slowly eastward from Mesopotamia and Greece.  Initially, the use of 
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opium was primarily linked to religion and mysticism.  However, later accounts in medical texts 
such as the ancient Egyptian Ebers Papyrus, describe medical uses for opium (Niewijk 2017). 
In the seventeenth century, recreational use of opium became popular soon after smoking 
tobacco became illegal in China. Opium dens, in which consumers bought and smoked opium, 
spread across China and in other countries.  England was the primary supplier of China’s opium 
when China outlawed its use.  Due to the profitability of opium, England attempted to prevent 
the criminalization of opium. After opium became illegal in China, England continued to sell 
opium, which led to the First and Second Opium Wars (Niewijk 2017). 
In the nineteenth century, the first widespread problem with opioids developed in the 
United States.  Opioids were used in the early 1860s to treat wounded soldiers’ pain during the 
American Civil War.  The Union alone issued 2.8 million ounces of opium powder and tincture 
and 10 million opium pills to their soldiers.  Consequently, many soldiers developed opioid 
addiction and dependency, especially to morphine.  In 1856, the hypodermic syringe was 
introduced, and by the 1870s, it was widely used to inject morphine.  While medical journals 
were filled with warnings about morphine addiction, many doctors were slow to heed the 
warning due to inadequate education and/or a lack of other pain treatments (Trickey 2018).   
In 1898, the Bayer Company was first to introduce commercialized heroin with the claim 
it was less addictive than morphine.  Heroin was ultimately found to be more addictive than 
morphine, and the ensuing opioid epidemic led the U.S. government to place restrictions on 
opioids in the 1910s and 1920s.  These restrictions included making heroin illegal and requiring 
that formal prescriptions be written in order to receive certain opioids and other narcotics 
(Trickey 2018). 
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Heroin use surged once again in the 1960s and 1970s in the United States, fueled in part 
by Vietnam War soldiers who were exposed to heroin while fighting overseas (STAT 2017).  
President Nixon responded by declaring a “War on Drugs” in 1971.   In 1973, the Drug 
Enforcement Agency was created by merging the Office for Drug Abuse Law Enforcement, the 
Bureau of Narcotics and Dangerous Drugs, and the Office of Narcotics Intelligence in an attempt 
to centralize federal efforts to control drug abuse.  In the early 1980s, the heroin crisis evolved 
into the “Crack Epidemic.”  The War on Drugs policies were expanded in 1986 when Congress 
passed the Anti-Drug Abuse Act of 1986, which allocated $1.7 billion to reduce drug activity 
(Augustyn and Lotha 2018, HarvardX).  Although the War on Drugs policies continue today, the 
peak of this effort was in the 1980s. 
2. How Opioids Rose to Prominence in Pain Treatment 
i. The Prevalence of Pain in the United States 
  Chronic pain is a prevalent medical condition in the United States.  More than 30% of 
Americans have some type of acute or chronic pain (Volkow 2016).  In a recent report, the CDC 
estimated that chronic pain affects 20.4% of adults and high-impact chronic pain affects 8.0% of 
adults in the population. The prevalence of pain is higher among women and older adults in 
addition to people who were previously but not currently employed, living in poverty, on public 
insurance and living in rural areas. While the impact of chronic pain is often associated with 
restrictions in daily activities, high impact chronic pain is debilitating, leading to “limitations in 
major life domains, including work, social, recreational, and self-care activities” (CDC 2018).  
ii. Early Opioid Studies Show Low Addiction Risk 
The high incidence of pain in the United States created an increased demand to manage 
pain.  Drugs, especially opioids, appeared to be a good solution.  In 1980, Porter and Jick wrote a 
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five-sentence letter to the editor of the New England Journal of Medicine. Published in the 
correspondence section, the letter suggested that addiction was rare among their patients. Their 
patients did not have a history of addiction and were being treated for acute pain in a hospital 
setting (Collins 2018, Zhang 2017).1  Portenoy and Foley (1986) also suggested that the risk of 
opioid addiction was low after observing 38 patients with chronic pain.  Neither of these cases 
focused on patients with non-malignant pain, and neither study was scientifically rigorous. Dr. 
Jick’s letter was based on information collected by his graduate student, Porter. She had been 
asked to note the number of addictions that occurred among their patients. Both the Jick and 
Porter (1980) and the Portenoy and Foley (1986) observations were used as evidence that the risk 
of addiction with opioid use was low. They also contributed to the perception that health care 
providers were allowing patients to suffer when their pain could be safely treated. Widespread 
dissemination of information from these observations lead to the rise of opioid prescriptions for 
acute non-chronic pain.. (Jones et al 2018). 
Clearly the published statements from Jick and Porter (1980) and Portenoy and Foley 
(1986) overstated the safety of opioid prescription drugs.  The impact of the addictive nature of 
opioids is significant.  The National Institute on Drug Abuse suggests that approximately 21% to 
29% of individuals with opioid prescriptions to treat chronic pain misuse them and between 8% 
and 12 % of these individuals develop an opioid use disorder (NIH 2019).  
 
 
1 “Recently, we examined our current files to determine the incidence of narcotic addiction in 39,946 hospitalized 
medical patients who were monitored consecutively. Although there were 11,882 patients who received at least one 
narcotic preparation, there were only four cases of reasonably well documented addiction in patients who had no 
history of addiction. The addiction was considered major in only one instance. The drugs implicated were 
meperidine in two patients, Percodan in one, and hydromorphone in one. We conclude that despite widespread use 
of narcotic drugs in hospitals, the development of addiction is rare in medical patients with no history of addiction.” 
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iii. Pain as a Vital Sign 
Pain management policy in the United States during the late twentieth century reflected 
both the current attitudes towards patients that suffered with pain and a rise in disabled war 
veterans.  Both factors led to a perception that pain was undertreated and to an increased focus 
on treating pain.  In an effort to reduce the perceived inadequate treatment of pain, the American 
Pain Society (APS) campaigned for pain to be recognized as the 5th vital sign in 1996.  Prior to 
1996, the vital signs that were measured included body temperature, pulse rate, respiration rate, 
and blood pressure.  These vital signs were assessed with medical instruments.  The goal of the 
APS campaign was to ensure that pain assessment was recognized as an equally important 
measure of patient wellbeing as the other four vital signs.  In 1999, the VA Hospital System also 
recognized pain as a vital sign (Koepke et al 2018).   Initially, the campaign was widely 
supported by regulatory organizations, medical societies, and pharmaceutical companies 
(Bernard 2018). 
The APS guidelines suggested that pain should be measured and recorded in a way that is 
visible using unidimensional pain scales and carefully monitored by members of the health care 
team (Bernard 2018).  However, the interpretation of these guidelines became problematic 
because a patient’s self-assessed pain level is subjective and may differ substantially among 
patients.   
This APS campaign to make pain the 5th vital sign had implications that were important 
in contributing to the development of the opioid crisis.   One of the most significant 
consequences was the impact on the Joint Commission on Accreditation of Healthcare 
Organizations (JCAHO), the hospital credentialing agency.  The JCAHO agency taught 
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healthcare professionals to assess and treat pain.2  They also required that pain scores be 
documented (Koepke et al 2018, Alam and Juurlink 2016).   
The APS campaign also affected the United States Hospital Consumer Assessment of 
Healthcare Providers and Systems (HCAHPS) survey.  The HCAHPS survey is a patient 
satisfaction survey that facilitates reimbursement to US healthcare providers. It is used by the 
Centers for Medicare and Medicaid Services (CMS) (Bernard 2018).  Following the recognition 
of pain as the 5th vital sign, a question was added to the survey that asked how well the hospital 
staff was treating a patient’s pain.  This question led to the unintended consequence of 
encouraging more aggressive pain treatment in response to a patient’s self-reported numerical 
pain scores.  The aggressive pain treatment often came in the form of opioid prescriptions which 
otherwise may not have been prescribed if physicians were not being assessed based on 
responses to the survey’s pain treatment question.  The responses to the survey were also used in 
evaluating the amount of funding a facility received, thus creating an additional incentive to 
adjust treatment to get high scores on pain management questions in the survey.     
  It has been suggested that the APS ‘pain as the 5th vital sign’ campaign has directly 
contributed to the ongoing opioid epidemic in the United States.  The American Medical 
Association, the American College of Surgeons, JCAHO, The American Academy of Family 
Physicians, and the Centers for Medicare and Medicaid services no longer support or advocate 
the recognition of ‘pain as the fifth vital sign’ campaign.  This pain management policy is seen 
has one of the greatest mistakes in medical history (Levy 2018). 
 
 
2 Pharmaceutical companies funded and wrote educational material for JCAHO regarding pain assessment and 
management. 
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iv. Marketing for Opioids in the Pharmaceutical Industry 
Pharmaceutical companies also played a role in causing the opioid epidemic by 
aggressively marketing opioid pain medications.  The most well know company was Purdue 
Pharma.  Following the widespread recognition of pain as the 5th vital sign by the medical 
community and the increased acceptance of opioids to manage pain, the demand for opioid 
medications increased.  In 1996, Purdue Pharma introduced OxyContin to relieve pain as part of 
an extensive marketing plan.  As OxyContin sales increased from $48 million in 1996 to around 
$1.1 billion in 2000, the high availability of OxyContin was associated with increased opioid 
abuse.  From 1996 to 2001, Purdue Pharma’s marketing plan included conducting forty national 
pain-management and speaker-training conferences at resorts where more than 5,000 physicians, 
pharmacists, and nurses attended.  Purdue Pharma promoted OxyContin among primary care 
providers for more liberal use, and by 2003, primary care providers made up almost half of all 
physicians prescribing OxyContin.  Purdue Pharma also promoted the idea that the risk of 
addiction from OxyContin was extremely low (less than one percent) and cited Porter and Jick’s 
(1980) note in the New England Journal of Medicine to support their claims (Van Zee 2009).3 
v. A Summary of the Causes of the Opioid Crisis 
 Although the causes of the opioid crisis were multifaceted, primary factors were an 
increased demand for pain treatment, two widely cited notes based on observations of patients 
with acute and chronic pain underestimating opioid addiction risk, a recognition as pain as a vital 
sign, and aggressive pharmaceutical marketing for opioid prescriptions.   
 
3 After performing a bibliometric analysis of the Jick and Porter (1980) correspondence from its publication until 
March 30, 2017, Leung et al (2017) conclude that it was “heavily and uncritically cited as evidence that addiction 
was rare with long-term opioid therapy.” In particular, the authors found 608 citations of the correspondence and 
noticed a sizable increase after OxyContin was introduced.  
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As the opioid crisis has evolved, many of the participants responsible for increased opioid 
use have admitted their role in the crisis.  Dr. Jick was mortified that his note was used by 
pharmaceutical companies to provide evidence that opioid use was safe and to promote their 
opioid drugs. He later regretted publishing his 1980 letter to the editor.  In 2017, the editor of the 
New England Journal of Medicine added a cautionary statement to the Porter and Jick letter. The 
statement warned readers of its misleading citation (Zhang 2017).4   
As mentioned earlier, the acceptance of pain as a fifth vital sign has been seen as one of 
the biggest mistakes in medical history.  The APS campaign for ‘pain as the 5th vital sign’ lost 
its support from regulatory organizations, medical societies, and pharmaceutical companies.  
Both the American Medical Association (AMA) and American Academy of Family Physicians 
(AAFP) removed pain as a vital sign in 2016.  The AMA also publicly apologized for the 
physicians’ role in the crisis due to their pressure to treat pain (Gart 2017).  
In 2017, Purdue Pharma pleaded guilty to a felony charge of misbranding OxyContin 
while marketing it as a safe and low addiction risk pain medication (Meier 2018).  Three 
executives pleaded guilty to a misdemeanor misbranding charge.  The company and the 
executives paid a combined $634.5 million in fines.  However, Purdue Pharma’s legal problems 
are not over.  There are more than 2000 lawsuits against the company for its part in the Opioid 
Crisis.  On September 15, 2019, Purdue Pharma announced an agreement in principal to settle 
the opioid litigation.  Key requirements of the settlement are detailed on their website. All of 
Purdue’s assets will be contributed for the benefit of the American public due to this settlement. 
The settlement is estimated to provide more than $10 billion to address the opioid crisis, 
 
4 On NEJM’s website, the Porter and Jick letter now has an editor’s note that reads, “For reasons of public health, 
readers should be aware that this letter has been ‘heavily and uncritically’ cited as evidence that addiction is rare 
with opioid therapy.” 
 12 
 
including the potential to provide millions of doses of life-saving opioid overdose reversal 
medications. Finally, Purdue will use Chapter 11 reorganization to finalize and implement the 
settlement agreement (Purdue Pharma 2019). 
Although Purdue Pharma was the most well-known of the companies involved in the 
opioid crisis, other pharmaceutical companies also face lawsuits.  Recently, the drug 
manufacturer, Teva Pharmaceuticals, and three drug distributors reached a settlement with two 
Ohio counties for $260 million (Hoffman 2019).  John Kapoor, the founder of a pharmaceutical 
company, Insys Therapeutics, has recently been sentenced to 5 years and 5 months in prison for 
leading a racketeering conspiracy.  Kapoor oversaw a scheme to bribe medical professionals to 
use his opioid-based pain reliever, Subsys (Chandna 2020). He is the first pharmaceutical 
executive in the United States to be sentenced for his involvement in the opioid crisis. 
3. Evolution of Opioid Substances Abused  
 While opioid prescription drugs paved the course for millions of Americans to develop 
opioid addiction, opioid prescription drugs were not the only type of opioids abused.  In 2010, 
the FDA approved the reformulation of OxyContin, allowing Purdue Pharma to begin 
distributing the reformulated product with the hope that it would be more difficult for abusers to 
break the pill down for injection, snorting, chewing, and smoking (Burke 2011).  However, the 
demand for opioids did not decrease.  Instead, the reformulated OxyContin was responsible for 
many addicted individuals substituting illicit opioids, heroin or fentanyl (Cicero 2012).  Heroin is 
a cheaper and more easily manufactured semi-synthetic opioid alternative to expensive 
prescription opioids. In 2017, an estimated 494,000 people in the United States (12-years or 
older) reported heroin use in the past year (CDC 2019).  The overdose deaths from heroin 
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increased fivefold from 2010 to 2017 (CDC 2019).  While heroin is still a relatively uncommon 
drug in the United States, its use is growing in all demographic areas. 
 Drug overdoses from fentanyl have also increased rapidly during recent years.  Beginning 
in 2013, overdose deaths increased every quarter.  During the years 2013 - 2014, the death rate 
more than doubled, almost doubled during the years 2014 - 2015, and more than doubled 
between the years 2015 - 2016 (Spencer et al 2019).  Fentanyl is a synthetic opioid that is 
cheaply manufactured and is easily available.  Its potency is 50 to 100 times greater than 
morphine.  Fentanyl is available in a variety of forms such as tablets, powder, liquid, and 
patches; therefore, it is frequently mislabeled or mixed with other drugs in the black market.  As 
obtaining prescription opioids becomes harder and opioid addicts substitute heroin, the exposure 
to fentanyl increases. (Carney 2019)  
 Illegal drug networks have pushed heroin, fentanyl, and counterfeit pharmaceuticals into 
suburban and rural areas in recent years.  In the past, rural areas were less affected than urban 
areas by drug trafficking.  Recent trends suggest that there has been an increase in drug 
trafficking in rural areas.  On average, rural populations are older than urban populations, so 
residents tend to have a greater demand for chronic pain management.  Furthermore, chronic 
pain and injury are more common in rural than in urban areas which has led to higher rates of 
drug overdose deaths in rural counties, including deaths related to opioids.   Opioid overdoses in 
rural counties have increased at a rate more than three times the increase in urban counties 
(Keyes et al 2014).   
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4. The Current State of the Opioid Epidemic  
i. Trends in the Opioid Crisis 
Chronic pain is a prevalent medical condition in the United States. As mentioned earlier, 
the CDC estimated that chronic pain affects 20.4% of adults and high-impact chronic pain affects 
8.0% of adults in the population. In spite of its prevalence and severity, chronic pain is complex 
and difficult to manage. After increasing dramatically, opioid prescriptions reached their peak in 
2012 at a rate of 81.3 prescriptions per 100 persons. Although the national prescribing rates had 
fallen to 58.7 prescriptions per 100 persons by 2017, the variation in prescribing rates was 
substantial among states and counties. For example, 16% of counties in the U.S. had prescribing 
rates sufficient for every person in the county to have a prescription, and some counties had 
prescribing rates that were seven times the national level (CDC 2018).  
The rise in opioid abuse has been accompanied by deaths due to opioid overdoses. The 
statistics highlight the seriousness of the opioid problem. Data from the CDC indicate an 
approximate six-fold increase in opioid overdose deaths since 1999. More than 47,000 people 
died of an opioid overdose in 2017, and 36% of those deaths involved prescription opioids (CDC 
2018).  Opioid related deaths have contributed to a decline in the U.S. life expectancy for the 
third year in a row (Haskins 2019, Bernstein 2019).   
The opioid crisis has also led to other problems.  For example, many addicts share 
needles when using drugs.  It is estimated that a fourth of the new HIV infections each year in 
the United States are due to sharing needles while injecting drugs.  The increase of new HIV 
infections affects public health negatively and costs millions of dollars for treatment (Sullivan 
2005).  In addition, because drug abuse is recognized as a major problem for society, tougher 
penalties for drug offenses in the U.S. have led to a significant increase in individuals 
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incarcerated (Chandler et al 2009).  The rise in imprisonment has additional negative effects on 
the economy as the labor force declines and public funds are reallocated to the prison system.  
The economic burden of prescription abuse of opioids alone has been estimated to be $78.5 
billion annually for the United States.  This estimate includes healthcare costs, the cost of 
addiction treatment, lost productivity, and criminal justice costs (NIH 2019, Florence 2016).  The 
burden for communities due to opioid use varies substantially throughout the United States and is 
related to factors based on socioeconomic, demographic, and community level differences. 
The latest report from the IQVIA Institute for Human Data Science showed that 
prescription opioid dosage volume declined 17 percent in 2018, marking the single-largest 
annual drop ever recorded within the United States.  Although overdose deaths involving 
prescription opioids have declined, overdoses from other types of opioids continue to show an 
increase (Ingraham 2019). 
ii. Policies to Prevent Opioid Misuse   
 Efforts to prevent opioid misuse are ongoing and evolve with new information about the 
epidemic.  Strategies include decreasing both the supply of and the demand for opioids in 
addition to reducing harm to drug users.  For example, the majority of hospitals have adopted 
policies limiting patient opioid prescriptions to seven days.   Prescription drug monitoring 
programs (PDMP) have also become widespread.  These programs restrict patients from “doctor 
shopping,” the process of going to multiple medical doctors until the desired prescription is 
received.  Pharmacies are also part of the solution through compliance programs, appropriate 
drug disposal, patient education, security initiatives, and increasing naloxone access (NACDS 
2019).  Medical cannabis laws have also been shown to reduce opioid misuse.  State medical 
cannabis laws legalizing the use of medical marijuana are associated with both lower prescribing 
 16 
 
rates and significantly lower state level opioid overdose death rates (Bachhuber et al 2014, Wen 
and Hockenberry 2018).   
iii. Treatments for Opioid Addiction  
Even though opioid addiction is treatable, in practice, it is often untreated and stigmatized 
(Chandler et al. 2009).  Strictly cutting off the supply of an individual’s opioids is not an 
adequate approach to help addicted individuals.  In order for treatment to be effective, it must be 
tailored to the individual patient as addiction often comes with other illnesses such as depression 
or anxiety disorder.  The most effective treatment for opioid addiction usually includes a 
combination of therapy and medication (Dennis et al 2007).  However, only 17.5% of people 
with a prescription use disorder received individual treatment in 2016. Methadone, 
buprenorphine, and naloxone are the three commonly used medications.  Methadone, a long-
acting synthetic opioid agonist medication, can prevent withdrawal symptoms and reduce 
craving in opioid-addicted individuals. Buprenorphine, a synthetic opioid medication, acts as a 
partial agonist at opium receptors and is able to reduce or eliminate withdrawal symptoms.  
Naloxone is an opioid antagonist. It binds to opioid receptors and can reverse and block the 
effects of other opioids; therefore, it is used to temporarily reverse the effects of an opioid 
overdose such as slowed or stopped breathing. Although highly effective, these medications are 
underutilized.  Less than 50% of treatment programs in the private sector offer these medications 
and only a third of eligible patients actually receive them (NIDA 2018).   In 2015, the Secretary 
of Health and Human Services announced five initiatives to address the opioid crisis: 1) improve 
access to treatment and recovery services; 2) promote the use of overdose-reversing drugs; 3) 
strengthen our understanding of the epidemic through better public health surveillance; 4) 
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provide support for cutting-edge research on pain and addiction; and 5) advance better practices 
for pain management (NIDA 2018).  
C.  Summary 
The introduction to this thesis has provided background information in which to 
contextualize the opioid epidemic.  The scope of studies needed to fully understand the opioid 
epidemic includes research on addiction, opioids, pain management, policy, and treatment for 
opioid abuse.  An implication of this literature is that a successful solution to the opioid epidemic 
must be multifaceted involving research efforts in many disciplines.   
As mentioned previously, a significant measure of the seriousness of opioid addiction is 
the number of overdose deaths.  Despite the risk of addiction and overdose, opioids are 
commonly prescribed to combat pain.  This paper uses cross-sectional county and state level 
panel data to examine the socioeconomic, demographic, and community level factors that are 
important in explaining opioid overdoses. 
Section II includes a review of the literature.  Empirical studies that examine the factors 
related to opioid overdose deaths are discussed.  A theoretical model of rational addiction is 
presented in Section III. Section IV develops two empirical models for an analysis of opioid 
deaths based on state and county level data. The empirical results are also discussed. Section V 
offers conclusions. 
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II. A Review of the Literature: Risk Factors Associated with Opioid Abuse 
 In a systematic review of factors related to opioid overdoses in the United States and 
Canada, King et al (2014) organize opioid mortality risk factors into three broad categories that 
include prescriber behavior, user behavior and characteristics, and environmental and systemic 
determinants. 
A. Prescriber Behavior 
The behavior of prescribers has been shown to play a key role in opioid-related overdose 
deaths.  Prescriber behaviors related to an increase in overdoses include prescribing opioids to 
more patients, prescribing opioids to patients frequently, prescribing opioids in higher dosages 
and prescribing more potent opioids such as methadone and oxycodone (King et al 2014).  
Opioid prescribing varies greatly among physicians.  Some studies suggest that prescriber 
behavior is linked to prescriber characteristics. For example, a physician’s prescribing behavior 
varies with the type of medical training received, resident specialty, or physician bias (Leventhal 
et al 2019, Todd et al 1994). 
1. Opioid Prescription Sales and High-Volume Prescribing  
Empirical research suggests that opioid related mortality is associated with both the 
number of patients receiving opioid prescriptions and how frequently (volume) a physician 
prescribes opioids.     
Opioid sales, substance abuse treatment admissions related to opioid pain relievers, and 
opioid overdose deaths increased significantly from 1999 to 2009 (Paulozzi et al 2011b).  
Paulozzi and Ryan (2006) examine opioid overdoses at the state level and find that the variation 
in the availability of opioid painkillers is related to the spatial distribution of drug overdose 
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deaths.  States with lower opioid death rates have lower rates of both opioid pain reliever sales 
and nonmedical use of opioid pain relievers (Paulozzi et al 2011b). 
Dhalla et al (2011) examine volume prescribing behavior and find that opioid deaths are 
concentrated among patients treated by physicians who prescribe opioids frequently. In addition, 
a study by Kim et al (2016) suggests that patients receiving opioids from high-volume 
prescribers have a higher probability of prescription overlap with other opioids and 
benzodiazepines. 
2. Opioid Dosage 
As opioid prescriptions and sales increased, the prescribed dosages also increased (King 
et al 2014).  Research suggests that opioid prescriptions in high doses are associated with an 
increased risk of opioid overdose deaths among patients receiving opioid prescriptions for pain.   
Bohnert et al (2011) examined the records of patients with cancer, chronic pain, acute pain, and 
substance use disorders.  They analyzed the relationship between the maximum prescribed daily 
opioid dose, dosing schedules, and the risk of opioid overdose death. Their results suggest that 
the risk of opioid overdose is positively related to the maximum prescribed daily dose of opioid 
medication.  Gomes et al (2011) also compared the number of opioid overdose deaths among 
patients treated with varying daily doses of opioids.  Their results support those reported by 
Bohnert et al (2011) and also suggest a strong association between the number of high dose 
opioid prescriptions dispensed and opioid-related mortality. 
3. Prescription of Methadone and Oxycodone  
Prior to 1990, opioid prescriptions for weaker opioids such as codeine were commonly 
used to treat pain.  However, prescriptions using more potent opioids such as methadone and 
long-acting formulations of oxycodone increased rapidly (Manchikanti et al 2008, Paulozzi 
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2009).  Paulozzi and Ryan (2006) examine state data and find that opioid mortality rates are 
significantly correlated with the use of methadone and oxycodone.   
Methadone is a long-acting synthetic opioid agonist medication that is used both to 
relieve pain and to reduce or prevent substance abuse.  It can prevent withdrawal symptoms and 
reduce craving in opioid-addicted individuals.  Although methadone dosing is challenging 
because the difference between therapeutic and toxic levels is minimal, it is a cheaper generic 
drug; therefore, physicians may prefer it for patients who use private or government sponsored 
insurance (King et al 2014).  Paulozzi et al (2012) examine the relationship between methadone 
prescriptions and opioid overdoses.  They find that the overdose death rate from methadone is 
significantly greater than the overdose death rates from other types of opioid prescriptions.  
Results from Webster et al (2011) support their conclusions. They find that although methadone 
makes up less than 5% of opioid prescriptions, it is involved in one third of opioid overdose 
deaths and 30% of all drug overdoses treated in emergency departments.  
Oxycodone is a powerful opioid and a popular prescription drug among providers due to 
its long-acting pain relief.  It is the primary ingredient in OxyContin, one of the most abused 
prescriptions (Juergens 2019a).  Oxycodone prescriptions rose rapidly between 1991 and 2007, 
increasing by 850%. Dhalla et al (2009) found that the increase in oxycodone prescriptions were 
accompanied by a fivefold increase in oxycodone-related overdose deaths.  As mentioned 
previously, due to the widespread abuse of these prescriptions, the FDA approved the 
reformulation of OxyContin in 2010 in order to make it more difficult for abusers to break the 
pill down for misuse (Burke 2011).  Havens et al (2014) find that abuse of the original extended 
release formulation of oxycodone fell significantly after the reformulation of OxyContin. 
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Additionally, they find no evidence that the reformulated extended release formulation was 
substituted for the original extended release formulation.  
4. Prescriber Characteristics 
Empirical studies have examined the relationship between prescriber characteristics and 
prescriber behavior. For example, the type of training and resident specialty of prescribers might 
affect the dosage and the quantity of opioid prescriptions that they write.  Leventhal et al (2019) 
examine opioid prescribing practices of emergency physicians based on their level of training or 
resident specialty.  They compare milligram equivalents (MME) of morphine prescribed to 
patients.5   Their results suggest that non-emergency department residents placed in emergency 
departments prescribe larger amounts of opioids. 
Other studies have analyzed how physician bias may influence perceptions of the severity 
of a patient’s pain.  Todd et al (1994) examine the difference between patient and physician 
estimates of pain severity for Hispanics and non-Hispanic whites.  They find no difference in the 
severity of pain in Hispanic and non-Hispanic white patients or in the disparity between patient 
and physician pain assessments.  Their results imply that Hispanic and non-Hispanic white 
patients are given the same prescriptions; therefore, there should be no difference in the 
likelihood of opioid addiction due to a difference in opioid prescriptions.  Tamayo-Sarver et al 
(2003) find similar results when they examine pain prescriptions in a national sample of 
emergency departments. Their analysis of data on pain prescriptions for black, Latino, and white 
patients indicate no significant correlation between race and prescriptions.  However, physicians 
were less likely to prescribe opioids to blacks relative to whites and Latinos. 
 
5 Morphine milligram equivalents (MME) or morphine equivalent doses (MED) are standard values based on 
morphine and its potency when compared to another opioid drug (Labonville 2016).   
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B. User Behavior and Characteristics  
The behavior and the characteristics of an opioid user may increase the risk of an opioid 
related death.  User behavior which may contribute to opioid overdoses includes diversion, 
doctor or pharmacy shopping, and using multiple drugs.  User characteristics linked to an 
increase in opioid related mortality include mental health status and sociodemographic 
characteristics (King et al 2014, Davis et al 2017).  
1. Prescription Drug Diversion and Doctor or Pharmacy Shopping 
Prescription drug diversion is “the unlawful channeling of regulated pharmaceuticals 
from legal sources to the illicit marketplace” … it “includes transferring drugs to people they 
were not prescribed for” (Wood 2015).  Doctor or pharmacy shopping are two ways in which 
prescriptions may be diverted.  Doctor or pharmacy shopping occurs when patients visit more 
than one doctor or pharmacy to obtain prescriptions.  Although data restrictions make it difficult 
to quantify the exact number of opioid overdoses in which diversion has played role, empirical 
studies suggest that doctor or pharmacy shopping is associated with an increase in opioid deaths.       
Hall et al (2008) examine the records of all West Virginia residents who died of 
unintentional pharmaceutical overdoses in 2006.  They find that pharmaceutical diversion was 
linked to 63.1% of those deaths while doctor shopping was associated with 21.4% of them.  They 
conclude that a majority of overdose deaths in West Virginia were associated with the diversion 
of prescription opioids and nonmedical opioid use.  Peirce et al (2012) also examine drug 
diversion in West Virginia.  They compared living subjects receiving opioid prescriptions with 
individuals who died from an opioid drug overdose for evidence of doctor and pharmacy 
shopping.  They find that the deceased subjects had a significantly higher number of doctor 
shoppers (25.21% versus 3.5%) and pharmacy shoppers (17.84% versus 1.3%).  They also find 
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that approximately 20.23% of doctor shoppers were also pharmacy shoppers and 55.60% of 
pharmacy shoppers were also doctor shoppers.  Their conclusions suggest the need for 
prescription monitoring programs to provide more prescriber oversight. 
McDonald and Carlson (2013) provide national estimates for doctor shopping. Their 
study is unique in two ways. First, they point out that prior estimates of doctor shopping were 
based on insurance claims or state drug monitoring programs.  Using those types of data, doctor 
shopping activity was estimated to occur with 0.2% - 13% of all opioid patients.  Because doctor 
shoppers often pay with cash to avoid being detected, McDonald and Carlson use a dataset that 
includes all opioid prescriptions dispensed to individuals across all retail pharmacies.  Second, 
prior estimates of doctor shopping activity were based on the professional judgement of 
physicians to define doctor shopping so the estimates had a lot of variability.  To overcome this 
problem, McDonald and Carlson developed a mathematical model that grouped patients by how 
many different prescribers they had visited within the past year.  This approach led to an 
“extreme” group of 135,000 likely doctor shoppers.  These individuals visited 10 different 
doctors on average and obtained approximately 32 opioid prescriptions in the prior 10 months.  
They find that although doctor shoppers make up 0.7% of all patients receiving opioid 
prescriptions, they purchase approximately 2% of all opioid prescriptions. 
Simeone (2017) examines doctor shopping activity with state data and finds that the 
number of diverted prescriptions declined from 1.75% of all prescriptions in 2008 to 1.27% of all 
prescriptions in 2012.  In addition, the number of morphine equivalent milligrams declined from 
2.95% of total metric tons in 2008 to 2.19% of total metric tons in 2012.  They note that their 
empirical analysis provides evidence that efforts to control diversion such as prescription 
monitoring programs have been effective.   
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2. Polydrug Toxicity 
Polydrug use refers to using more than one drug at a time to intensify the effects of a 
single drug.  King et al (2014) point out that many opioid related deaths also involve other drugs 
such as prescription medications for sedatives, additional opioid prescriptions, alcohol, and illicit 
drugs.  They suggest that opioid overdose may be “part of an epidemic of multidrug mortality” 
(p. 37).   
Numerous studies have linked polydrug toxicity and opioid abuse. Piercefield et al (2010) 
find that drug overdose deaths often involve multiple substances, and the most common 
substance is prescription opioids.    Over half of all alcohol-related emergency room visits 
involved illicit and prescription drugs in 2011 (Juergens 2019b).  Esser et al (2019) analyzed data 
from individuals who responded to questions about prescription opioid misuse and alcohol 
consumption.  Their research suggests that prescription opioid misuse was more prevalent among 
binge drinkers than nondrinkers and that one fifth of prescription opioid overdose deaths also 
involve alcohol.  Slavova et al (2017) find that many fatal fentanyl overdoses are associated with 
heroin adulterated with fentanyl and suggest that the lack of routine emergency department drug 
testing likely results in underreporting non-fatal overdoses involving fentanyl and other synthetic 
drugs. 
3. Mental Health Status 
Davis et al (2017) examine the relationship between mental health disorders due to mood 
and anxiety and prescription opioid use.  They estimate that 18.7% of Americans with mental 
health disorders use prescription opioids and adults with mental health conditions receive 51.4% 
of the total opioid prescriptions in the United States each year.  They also find that having a 
mental disorder significantly increases the likelihood of treating pain with opioids (18.7% versus 
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5.0%; p < 0.001).  Because more than half of opioid prescriptions in the United States go to the 
16% of Americans with mental health disorders, their results imply that improving pain 
management among the population with mental health disorders is critical to reducing national 
dependency on opioids.  An association between opioid use and suicide has also been found in 
empirical studies.  Ilgen et al (2016) examine opioid dosage as a potential factor for an increased 
risk of suicide among patients with chronic pain.   They find that the risk of suicide rises with an 
increase in the dose of opioid prescriptions. 
4. Sociodemographic Characteristics 
Opioid related deaths are related to sociodemographic characteristics such as age, race, 
ethnic background, gender, and socioeconomic status.  Deaths from opioid use are also related to 
whether opioid users reside in urban or rural areas.6  
Many empirical studies have examined the importance of sociodemographic factors in 
assessing the risk of opioid deaths. Paulozzi et al (2011a) examine the relationship between age, 
race, ethnicity, sex, and opioid overdose rates.  Although their results suggest that opioid 
overdose death rates are highest among individuals 35 to 54 years old, they conclude that 
differences in race, ethnicity, or demographics cannot fully explain state variations in opioid 
prescription sales or in nonmedical use of opioids. 
  King et al (2014) evaluate 22 studies that focused on sociodemographic differences. 
These studies suggest that, generally, opioid deaths are “higher among men, non-Hispanic 
Whites and American Indian/Alaska Natives, middle-aged individuals, those living in rural areas, 
 
6 Because socioeconomic factors are significantly correlated with urban or rural residential status, empirical studies 
often examine both characteristics.  A more complete discussion of the relationship between urban and rural 
residential status and opioid overdose risk is found in the last section on environmental and systemic 
determinants.  
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and those of lower socioeconomic status” (p. 36). However, they note “considerable 
heterogeneity” with these overall patterns.  Research also suggests that sociodemographic trends 
vary over time and with the specific drug.   
Empirical research by others support King’s conclusions.  Green et al (2010) provide 
evidence that an individual’s age and race may be correlated with abuse of a specific drug. They 
find that heroin-only deaths are higher among non-whites, are more likely to involve alcohol or 
cocaine, and typically occur in public locations and large cities. Alternatively, prescription 
opioid-only deaths are more likely to involve other medications and occur in suburban or rural 
locations, compared to heroin overdose deaths from methadone.  Jones et al (2015) find that non-
Hispanic whites experienced higher methadone overdose death rates than other racial or ethnic 
groups.  Alexander et al (2018) find that the opioid epidemic was primarily driven by heroin 
from 1979 to the mid-1990s.  Both white and black populations were affected. During the mid-
1990s to 2010, the increase in opioid mortality was driven by natural and semi-synthetic opioids 
among whites; however, there was no increase in mortality among blacks.  Heroin and synthetic 
opioids have been primarily responsible for the increase in opioid related mortality for both 
populations from 2010 to the present. 
Gender also plays a role in the risk of opioid overdose.  While more men die from drug 
overdoses than women, some studies indicate that the percentage increase in both opioid abuse 
and deaths is greater among women.  Jones et al (2015) find that men experience higher 
overdose death rates than women.  Mack et al (2013) find that opioid related overdose deaths for 
women increased fivefold between 1999 and 2010, while opioid overdose deaths among men 
increased 3.6 times.  They also find that emergency department visits related to misuse or abuse 
of opioids among women more than doubled between 2004 and 2010.  Binswanger et al (2013) 
 27 
 
used data from the prison system in the state of Washington to examine the factors responsible 
for mortality following release from prison between 1999 and 2009.  They find that opioids were 
related to 14.8% of all deaths and that women experienced an increased risk of an opioid-related 
overdose. 
C. Environmental and Systemic Determinants 
Empirical studies suggest that environment and systematic factors may be related to the 
risk of opioid-related deaths.  Environmental and systematic factors include area urbanization or 
socioeconomic status (SES), geography, economic opportunity, and interventions which focus on 
policies to reduce the supply of and the demand for opioids and to reduce harm. Other factors, 
such as state laws on Cannabis policy, may have an indirect impact on opioid overdoses.   
1. Urbanization or Socioeconomic Status 
Urban and rural residential status may be a factor in predicting the risk of opioid 
addiction. Guy et al (2017) suggest an association between higher opioid prescription rates and 
rural residence.  Lister et al (2019) examine opioid prescribing and opioid-overdose death rates 
in Michigan to compare urban and rural counties.  They find that urban counties have a high 
rates of opioid overdose deaths, but rural counties have higher rates of opioid prescribing. 
Paulozzi (2006) finds that the majority of publicity has focused on opioid abuse in rural areas 
such as Appalachia and that higher prescription drug overdose death rates have been reported in 
more rural areas within states.  However, Rigg et al (2018) find that opioid overdose death rates 
are not disproportionately higher in rural areas.  They suggest that infrastructural, 
socioeconomic, and social factors have contributed to the higher prevalence of opioid-related 
mortality in rural areas.  For example, they note that limited access to addiction treatment, 
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underdeveloped prevention workforces, lack of harm reduction programs, and health care 
shortages hinder rural communities from properly addressing the opioid crisis. 
The association between rural residence and opioid prescriptions may also be linked to 
doctor and/or pharmacy shopping and pill mills within rural communities.  “Pill mill” is a term 
that describes an illegal operation where a doctor, clinic, and/or pharmacy prescribes or sells 
prescriptions inappropriately (Rigg et al 2010). Hall et al (2008) suggest that many individuals 
have been successful in doctor shopping and that pill mills have been effectively distributing 
opioids to the public, especially in rural communities.   
 Peters et al (2019) use county level data to analyze opioid overdoses during the sub-
periods, 2002-2004, 2008-2012, and 2014-2016. They find that the type of opioids abused varies 
regionally.  They suggest that the opioid crisis involves several epidemics occurring at the same 
time. They identify three distinct epidemics (prescription opioids, heroin, and prescription-
synthetic opioid mixtures) and a syndemic which involves a population with more than one 
epidemic.  Syndemics are a set of linked health related issues that interact with each other and 
cluster in population subgroups, creating a greater burden for those subgroups (Shiel 2018). 
Peters et al (2019) find that each epidemic and syndemic affects different populations. The 
prescription opioid-related epidemic is associated with access to opioids from pharmacies and is 
most common in rural southern states. It affects urban and rural counties that have been “left 
behind” the rest of the nation.  The “left behind” counties are former agricultural and 
manufacturing communities that have been in decline since the 1990s.  These communities are 
less populated and more remote, older and mostly white, and have a history of drug abuse.  On 
the other hand, the counties most affected by heroin and the opioid syndemic are more urban, 
connected to interstates, ethnically diverse, and more economically stable. Peters et al (2019) 
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suggests that their research implies that multiple types of policies must be used to address the 
regionally diverse distinct types of epidemics.  
The latest CDC report by the National Center of Health Statistics (Hedegaard et al 2019) 
on urban-rural differences in drug overdose rates indicates that drug overdose deaths increased in 
both urban and rural counties during the period 1999 to 2017. However, the urban-rural 
differences in overdose death rates vary over time and by the type of drug involved. The 
following paragraph summarizes their conclusion:  
From 1999 through 2003, rates were higher in urban than in rural counties. Rates were similar 
from 2004 through 2006, then higher in rural counties from 2007 through 2015. In 2016 and 
2017, age-adjusted rates of drug overdose deaths were higher in urban than in rural counties. In 
2017, the rates of drug overdose deaths involving heroin, synthetic opioids other than 
methadone, and cocaine were higher in urban counties than in rural counties. In contrast, the 
rates of drug overdose deaths involving natural and semisynthetic opioids and involving 
psychostimulants with abuse potential were higher in rural counties than in urban counties. (p. 5) 
 
2. Geography 
Geographic variation in opioid prescribing patterns and opioid overdose death rates exists 
within the United States.  Schieber et al (2019) use state level data from 2006 to 2017 to analyze 
changes in opioid prescribing practices over time and how the changes are distributed across 
states.  They focus on six key prescription measures: “annual amount of opioids prescribed in 
morphine milligram equivalents (MME) per person; mean duration per prescription in days; and 
4 separate prescribing rates—for prescriptions 3 or fewer days, those 30 days or longer, those 
with a high daily dosage (≥90 MME), and those with extended-release and long-acting 
formulations” (p. 1). They find an increase in the mean duration and prescribing rate for long-
term prescriptions of opioids but a decline in the amount of opioids prescribed per person and in 
the prescribing rate for high-dosage prescriptions, short-term prescriptions, and extended-release 
and long-acting formulations. They point out that although some decreases were significant, the 
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results remained high. They also find significant variability (2- to 3-fold) in 5 of the 6 
prescribing measures among states.  
The most recent report on geographical variation in opioid related deaths by the CDC 
uses data from 2017. During this year, 70,237 drug overdose deaths occurred in the United 
States. The report indicated a significant increase of 9.6% in the age-adjusted rate of overdose 
deaths from 2016 (19.8 per 100,000) to 2017 (21.7 per 100,000).  During 2017, 47,600 overdose 
deaths involved opioids (67.8% of all drug overdose deaths). Synthetic opioids (other than 
methadone) were the primary opioids abused. The variability in drug overdose rates as 
summarized in the report (online) follows: 
In 2017, the states with the highest rates of death due to drug overdose were West 
Virginia (57.8 per 100,000), Ohio (46.3 per 100,000), Pennsylvania (44.3 per 100,000), the 
District of Columbia (44.0 per 100,000), and Kentucky (37.2 per 100,000). 
States with statistically significant increases in drug overdose death rates from 2016 to 
2017 included Alabama, Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, 
Indiana, Kentucky, Louisiana, Maine, Maryland, Michigan, New Jersey, New York, North 
Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, West Virginia, and Wisconsin. 
 
Although they focus on county data and rural-urban residence, Peters et al (2019) suggest 
that regional differences in opioid overdose mortality vary with the type of opioid. As mentioned 
earlier, three distinct epidemics (prescription opioids, heroin, and prescription‐synthetic opioid 
mixtures) and a syndemic are identified. They describe regional differences for each epidemic 
and syndemic. The prescription drug epidemic is concentrated in rural southern states where 
access to opioids involves local pharmacies. They point out that even though prescription drug 
overdose mortality from pharmaceuticals reached the highest level nationwide in 2013 and 
declined afterward, prescription opioids still present a problem in some areas. The heroin 
epidemic is most severe in western and Midwestern states with urban areas close to interstates 
with heavy drug trafficking, especially those used by cartels bringing in heroin from Mexico. 
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The synthetic opioid epidemic is most pronounced in urban areas in the Northeast. They also 
point out that these synthetic drugs are often mixed with heroin or cocaine. Finally, multiple 
opioid epidemics exist together (a syndemic) in areas of the country where the opioid crisis 
began, such as Kentucky, Ohio and West Virginia. 
3. Economic Opportunity  
Many empirical studies examine the relationship between economic opportunity, opioid 
prescriptions, and opioid abuse. Ghertner et al (2018) note that individual characteristics 
associated with opioid abuse include having low income, being uninsured, or receiving 
Medicaid. However, they point out that even though the individual level relationship is clear, the 
association between the level of opioid abuse and economic conditions in a community has not 
been fully examined.  
Empirical research results in studies of the relationship between economic conditions and 
opioid abuse are mixed.  Guy et al (2017) find that higher levels of unemployment are positively 
associated with higher levels of opioid prescriptions in county level data. They also find 
substantial variation in opioid prescribing patterns suggesting a lack of agreement on appropriate 
prescribing practices.  Hollingsworth et al (2017) find that an increase in the county 
unemployment rate by one percentage point is associated with a 3.6% increase in the opioid 
death rate. Some studies explore evidence of reverse causality, that is, that opioid abuse has a 
negative impact on labor market conditions.  Krueger (2017) finds a decline in labor force 
participation in areas with higher opioid prescriptions.  Similar to Krueger, Harris et al (2019) 
suggest that per capita opioid prescriptions have a significant negative effect on the labor force 
participation rate, employment-to-population ratio, and unemployment rate. Aliprantis et al. 
(2019) also find a strong negative link between opioid prescription rates and labor force 
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participation when using county level employment data.  They estimate that prescription opioids 
account for 44% of the decrease in male labor force participation from 2001 to 2015 in the U.S., 
with less educated men most affected. Ghertner and Goves (2018) explore the relationships 
between three measures of economic opportunity (poverty rates, unemployment rates, and the 
employment-to-population ratio), two measures of the prevalence of prescription opioids (retail 
opioid sales and Medicare Part D opioid prescriptions) and two measures of substance use (drug 
overdose deaths and opioid-related hospitalizations) using county level data. Their results 
indicate that overall, the opioid crisis has a greater negative impact on areas with lower economic 
activity. However, they note that the extent of the relationship varies with the region of the U.S. 
They point out that “counties differ in their economic, demographic, cultural, and political 
contexts” and further note that these factors may explain much of the diversity in the relationship 
p. 8). They also note that one limitation of their study is that it does not find a causal relationship 
between economic opportunity, the prevalence of opioids, and substance use.  
Papers by Ruhm (2018) and Currie et al (2018a) contribute to the issues raised by 
Ghertner and Goves (2018). Ruhm (2018) uses county level data from 1999-2015 to examine the 
contribution of the deterioration in medium-run economic conditions versus changes in the drug 
environment in explaining drug fatality rates. He finds a weak relationship between economic 
decline and drug mortality rates which is mostly explained by confounding factors. He finds that 
the risk of drug deaths varies over time and across population subgroups in a way that is 
consistent with the availability and cost of drugs.  Currie et al (2018a) examine the direction of 
the casual effect in the relationship between opioid prescriptions and employment. They use 
quarterly county level data on all opioid prescriptions filled at U.S. pharmacies from 2006 to 
2014. Their analysis includes three parts. Initial regressions examine how the employment-to-
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population ratio within an area changes as prescription rates vary. They do not find a significant 
relationship between changes in the per capita opioid prescriptions and changes in the 
employment-to-populations ratio.  They also estimate models of the effect of per capita opioid 
prescription rates on employment-to-population ratios, using opioid prescriptions for the elderly 
as an instrument for opioid prescriptions for younger ages, and models of the effect of 
employment-to-population ratios on opioid prescription rates using a shift-share instrument. 
Their results suggest that no simple causal relationship exists between economic conditions and 
opioid abuse. In a separate article, Currie and Schnell (2018b) point out that poor economic 
conditions are not responsible for the opioid epidemic. They also conclude their article with the 
statements below: 
What this means is that we must look at the opioid epidemic for what it is: a self-inflicted perfect 
storm that arose from a combination of newly available opioids, new attitudes about the 
importance of pain management, loose prescribing practices, and a lack of professional 
accountability. The solution to the problem must lie in addressing some of these root causes.    
(p. 4) 
 
4. Interventions 
Policy responses to the opioid epidemic include national, state, and community level 
efforts to reduce both the supply and demand for opioids and to reduce harm.  More education 
about opioids for providers, patients, and the public at the national level is one example. King et 
al (2014) discussed several studies that provide evidence that the guidelines, policies, and 
consensus statements about how to manage pain played a role in the number of opioid-related 
deaths.  In 1997, as opioids were encouraged to treat chronic pain, opioid-related mortality 
increased; however, new guidelines in 2007 with warnings about appropriate opioid dosages 
were followed by a reduction in opioid deaths. Prescription Drug Monitoring Programs at the 
state level is another example.  Prescription Drug Monitoring Programs restrict the availability of 
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opioids by discouraging patients from doctor shopping and providers from high-volume 
prescribing. All states but Missouri have legislation authorizing the creation and operation of a 
PDMP.  Interact for Health, an independent philanthropic foundation that serves the Greater 
Cincinnati area, represents a community response to the opioid epidemic.  The foundation 
developed an education campaign to reduce the stigma associated with opioid addiction, set up a 
regional hotline, and provides funding for harm reduction strategies such as naloxone 
distribution (Chubinski and Lydenberg 2020).   
The evidence on the success of various interventions is mixed. Doleac et al (2019) 
examine recent research on policies designed to decrease opioid abuse and opioid overdose 
deaths.  They focus on studies that attempt to quantify the casual effects of the policies on opioid 
abuse and mortality.  They point out that limiting the supply of opioids yet providing care for 
individuals who need the medication involves tradeoffs.  For example, PDMPs can reduce 
opioid-related mortality, but they may also induce opioid users to substitute illicit opioids such as 
heroin.  Additionally, harm reduction strategies are associated with positive outcomes for some 
but encourage risker opioid use among others.  
Doleac et al (2019) also notes that average effects sometimes mask important differences 
across states. For example, state laws regarding PDMPs vary. Some state laws require that 
doctors access prior prescriptions given to patients before writing a prescription; on the other 
hand, some states require only that information on prior prescriptions be provided.  If a state 
requires the use of information on prior prescriptions, then the law is a “must-access” PDMP.  
Meara et al (2016) examine the impact of a variety of state policies on the opioid prescriptions 
given to Medicare patients. They find that state policies such as PDMPs do not reduce opioid 
prescriptions. However, Buchmueller and Carey (2018) distinguish between states that require 
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that doctors access PDMP data and those states that do not. They find that must-access PDMPs 
significantly reduce measures of opioid misuse while voluntary PDMPs did not have a 
significant effect.  Ayres and Jalal (2018) use county level panel data on all opioid prescriptions 
in the United States to determine the effects of policies such as PDMPs.  They also find that 
PDMPs are most effective in reducing prescription rates if their use is required.   
Other policies may have an impact on opioid use or opioid prescribing practices even 
though they were not put into place with that specific goal. For example, many states have 
decriminalized cannabis while some states have passed legislation allowing the use of medical or 
recreational cannabis.  Bachhuber et al (2014) find that state laws allowing medical cannabis are 
associated with significantly lower opioid overdose death rates.  Livingston et al (2017) compare 
changes in the level of monthly opioid-related overdose deaths before and after Colorado 
legalized recreational cannabis. They find that legalization of recreational cannabis sales resulted 
in a 0.7 deaths per month decrease in opioid-related overdose deaths.  Bradford et al (2018) also 
find that medical cannabis laws are associated with significant reductions in opioid pain reliever 
prescribing in the Medicare Part D population.  Wen and Hockenberry (2018) analyzed the 
relationship between the state implementation of medical and recreational marijuana laws, opioid 
prescribing rates, and spending among Medicaid enrollees.  Their study suggested that medical 
marijuana laws are associated with a 5.88% decrease in opioid prescribing and recreational 
marijuana laws are associated with a 6.38% decrease in opioid prescribing. 
Ruhm (2018) points out that many empirical studies have been done on the effectiveness 
of a variety of policies on opioid abuse and opioid mortality. He mentions policies associated 
with medical marijuana, abuse-deterrent drug formulations, Naloxone availability, Medicare Part 
D, the availability of substance abuse treatment, advertising, and state policies influencing the 
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availability of prescription opioids. However, he concludes that each of these polices explain, “at 
most, only a small portion of the overall change in overdose deaths” (p.5). 
          A review of the literature suggests that understanding the opioid epidemic is complex and 
that effective policies to reduce opioid abuse must have an impact on prescriber behavior, user 
behavior. and the environment.  The policies must also be multifaceted and tailored to allow for 
regional differences.  
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III. Theoretical Model 
 Because addiction is a chronic disease, it is related to theories in health economics.  The 
most well-known theories that serve as a basis for the empirical work that follows are 
Grossman’s (1972) model of the demand for health and Becker’s and Murphy’s (1988) model of 
rational addiction. 
A. The Production of Health  
Grossman (1972) developed a model to explain an individual’s health. Grossman begins 
by assuming that people derive utility from health and a composite of all other goods. The utility 
function is: 
Ut = Ut (Ht, Gt) 
where Ht equals the stock of Health 
and Gt equals all other goods. 
Health is modeled as a production process. The production function of health summarizes 
the relationship between health inputs such as medical care and lifestyle and health outcomes 
such as life expectancy.  The model treats investment in one’s stock of health as a form of 
investment in human capital. Similar to other types of capital goods, the stock of health must be 
maintained by making investments in health that exceed the amount by which health stock 
deteriorates over time.  The change in health stock can be expressed as gross investment in 
health less depreciation of existing health stock which can be written as: 
∆Hj = Hj, t+1 – Hjt = Ijt – ∆jtHjt  
where ∆Hj equals net investment in health for individual j 
Hj, t+1 equals health stock at time t+1 
Hjt equals health stock at time t 
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Ijt equals investment in health for individual j at time t, and  
∆jtHjt equals the depreciation of health stock, where ∆jt equals the annual rate of 
depreciation in individual j’s health stock. 
Gross health investment (I) is a function of medical services (M) and the time devoted to 
the production of health (T). Individuals with more human capital (C) are more efficient 
producers of health.  Grossman also assumes that depreciation in health is related to age (A) and 
behavioral factors (B) such as alcohol consumption, smoking, and obesity which negatively 
impact health, as well as others, such as good nutrition and exercise, which have a positive effect 
on health.  The behavioral input also includes chemical dependency and addiction which lead to 
a deterioration in health stock.   
The gross investment in health function may be written as:  
Ijt = Ijt (Mjt, Tjt, Cjt, Ajt, Bjt).   
B. Rational Addiction 
Behavioral factors that involve addictions to goods such as cigarettes, alcohol, and illicit 
drugs are inputs in the production of health that have a negative impact on health status.  
However, if addictive goods change the utility function of individuals, preferences may not be 
time-consistent. Becker and Murphy (1988) develop a model in which individuals rationally 
choose to consume addictive goods. Their theory is based on the assumption that individuals 
incorporate all available information into their calculations of utility and that they are aware of 
the addictive properties that may change their future preferences. Therefore, preferences are 
time-consistent in their model.  Current consumption increases the desire for future consumption, 
and, as tolerance increases, the need to consume additional quantities of the addictive good in 
order to achieve the same effect.  The rational addict considers both the benefits and the harmful 
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consequences when choosing the level of consumption of the addictive good each period. Their 
model implies that addiction is more likely in individuals who discount the future heavily, that is, 
these individuals focus less on the future effects from current consumption choices.7 
Becker et al (1991) extend Becker and Murphy’s model by adding addictive capital stock 
to the utility function.  In this model, consumption of the addictive good leads to addictive 
capital stock that reinforces the desire for consumption of the addictive good as it makes future 
consumption more pleasant.  For example, an individual may begin smoking cigarettes knowing 
its addictive properties.  The initial cigarette may be unpleasant, but the experience becomes 
more pleasant over time.  The repetitive use of cigarettes reinforces the individual’s demand for 
the addictive good. As the addictive capital stock grows, current consumption of the addictive 
good increases.   The smoker will want to smoke more and more.  Addiction develops when 
individuals experience withdrawal symptoms as they stop consuming cigarettes.   
Models of addictive behavior have implications for the development of optimal public 
policy solutions.  The models above imply that since individuals take all information into 
account before deciding to consume an addictive good, any expected increase in price will 
decrease current consumption.  Therefore, government policy can be used to reduce tobacco 
consumption by increasing cigarette taxes. However, if the decision to consume addictive goods 
is rational, an implication of these models is that government regulatory policy towards addictive 
goods should depend only on interpersonal externalities.  Gruber and Köszegi (2001) extend 
Becker and Murphy’s model by assuming inconsistent preferences as individuals make decisions 
about smoking.  In this case, current levels of consumption of the addictive good may be too 
 
7 Although the assumption of rational choice may seem restrictive, some empirical studies offer support for Becker 
and Murphy’s model (Bentzen et al 1999) 
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high because individuals underestimate the ability to stop smoking in the future. In this case, 
optimal government policy solutions should consider both the externalities on others and the 
internalities on the addict. This model is especially relevant for highly addictive substances such 
as illicit drugs (Henderson 2018).  
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IV. Empirical Model 
            Theoretical models and empirical studies suggest that prescriber behavior, user behavior 
and characteristics, and environmental and systemic factors play a key role in determining opioid 
addiction.  The opioid overdose mortality rate is the most commonly used measure of opioid 
addiction in the empirical literature. This paper develops empirical models based on state and 
county data to investigate the relationship between variables used to measure prescriber 
behavior, user behavior and characteristics, and environmental and systemic factors and opioid 
overdose deaths. For each level of analysis, the variables used in the empirical model and data 
are described in the first section followed by a discussion of the empirical results in the second 
section.  
A. State Level Analysis  
1. Data 
The first empirical model uses state level panel data for the years 2014-2015 to examine 
factors related to opioid overdose deaths in the United States.  Only the states that had values for 
all of the variables used in the empirical model are included in the analysis. The states include 
Arizona, Arkansas, Colorado, Florida, Georgia, Hawaii, Iowa, Kentucky, Maine, Maryland, 
Massachusetts, Michigan, Minnesota, Nebraska, Nevada, New Jersey, New Mexico, New York, 
North Carolina, Oregon, Rhode Island, South Carolina, Texas, Vermont, Virginia, Washington, 
West Virginia, and Wisconsin. There are 56 observations used in this study. All of the data 
excluding the cannabis law data was obtained from the State Health Access Data Assistance 
Center (SHADAC).  Data for cannabis laws was gathered from a historical timeline on 
ProCon.org.   
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2. Model Specification and Regression Results 
As discussed earlier, previous research suggests that prescriber behavior, user behavior 
and characteristics, and environmental and systemic factors are related to opioid overdose 
mortality.  Proxies for each of these factors are used to develop the empirical model.  
Prescription sales of oxycodone (PSO) and hydrocodone (PSH) per 100,000 persons are 
included as variables to measure prescriber behavior within a state. Sales of both drugs increase 
access to opioids and make opioid addiction more likely. Both variables are expected to be 
positively associated with opioid overdose deaths.  (Paulozzi et al 2011).   
Four variables are used as measures of user behavior and characteristics. The variables 
include the percentage of individuals in the civilian non-institutionalized population with at least 
one visit to the emergency department during the past twelve months (ED), binge drinking 
behavior measured as the percent of adults consuming four (women) or five (men) or more 
drinks on one occasion during the past 30 days (BD), firearm suicides per 100,00 persons (SUI), 
and preventable hospitalizations per 100,000 persons (PH).  Potentially preventable 
hospitalizations are admissions to a hospital for certain acute illnesses or worsening chronic 
conditions that might not have required hospitalization if the condition been managed 
successfully by a primary care provider (Moy et al 2013). This measure may also be interpreted 
as the tendency for individuals to overuse emergency rooms and urgent care in place of primary 
care (Brumley et al 2007).  
The rate of emergency department visits is expected to be positively associated with 
opioid overdose deaths. Prior studies have identified frequent visits to the emergency department 
as a marker for opioid abuse. The frequency of emergency department visits has been linked to 
nonmedical opioid use, drug diversion and poorly managed pain.  Brady et al (2015) find a 
 43 
 
strong association between the rate of emergency department visits and an increased risk for 
overdoses from prescription drugs.  
Theory suggests that the net effect of binge drinking on opioid overdose deaths is 
ambiguous because alcohol may be a complement to or a substitute for opioid use. Esser et al 
(2019) find evidence of a complementary relationship as binge drinkers were almost twice as 
likely as nondrinkers to misuse prescription opioids. 
States with a greater number of firearm suicides and preventable hospitalizations are 
expected to have more opioid overdose deaths. Both variables are associated with mental 
disorders, chronic pain, and substance abuse.  (Meiman et al 2015; Ilgen et al 2016; Martin 
2018).  
Four variables are used to measure environmental and systemic factors. The variables 
include the unemployment rate (UR), the amount of state public health funding per person (F), 
the state excise tax on cigarettes (CT) and the existence of laws allowing medical or recreational 
cannabis (C).  
The net effect of the unemployment rate on opioid overdose deaths is ambiguous.  
Theoretically, as the unemployment rate increases and economic conditions decline, an increase 
in opioid abuse and overdoses would be expected. However, as discussed earlier in the review of 
the empirical literature, evidence on the relationship between the unemployment rate and the 
opioid overdose rate is mixed (Currie and Schnell 2018).  Some studies find a positive 
relationship between the unemployment rate and opioid overdose deaths while other studies find 
that the relationship between economic conditions and opioid deaths is weak once the 
availability and cost of drugs are considered. Additional studies also find evidence of reverse 
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causality between these two variables, that is, opioid abuse has a negative impact on the 
unemployment rate (Harris 2019).  
The net effect of state public health funding per person on opioid overdose deaths is 
ambiguous. While state public health public funding can be used to increase measures to combat 
the opioid epidemic, public health funding also increases access to health care and pain 
prescriptions such as opioids. 
In theory, the impact of the state excise tax on cigarettes on the opioid overdose death 
rate is ambiguous, depending on whether cigarettes serve as a substitute or a complement to 
opioid use. If cigarettes are a substitute for opioids, an increase in the excise tax on cigarettes 
would reduce cigarette consumption and increase opioid abuse and overdoses. If cigarettes and 
opioids are complements, an increase in the excise tax on cigarettes would have the opposite 
effect on opioid overdoses. There is some empirical research to suggest that cigarettes and 
opioids are complements. Michna et al (2004) find that cigarette smoking is associated with a 
higher risk of opioid abuse. Chun et al (2009) studied the smoking behavior of patients being 
treated for opioid addiction and find that heavier smoking activity is associated with a stronger 
drug addiction.  
A dummy variable is used for state laws which allow the use of medical or recreational 
cannabis (1 = the use of medical marijuana or recreational cannabis is legal). Opioid overdose  
deaths have been driven by prescriptions to treat chronic pain. Because medical cannabis is used 
to treat pain, states in which medical cannabis is legal may have lower rates of opioid abuse and 
overdose deaths. Bachhuber et al (2014) find that medical cannabis laws are associated with 
significantly lower state level opioid overdose mortality rates. Additional studies have examined 
opioid overdose death rates in states that have legalized marijuana for recreational use such as 
 45 
 
Colorado, which experienced a 7% drop in opioid related mortality. However, one meta-analysis 
suggests that while legalizing marijuana is associated with a small reduction in opioid 
prescriptions, the impact on opioid overdose deaths is inconsistent (Chihun and Li et al 2019).  
Because panel data is used, a dummy variable for the year (0 = 2014; 1 = 2015) is 
included to capture time fixed effects, that is, the possibility that factors not captured in the 
model affect all variables and vary from one year to year.  
An explanation of the variables and descriptive statistics is in Table 1.  Descriptive 
statistics are computed from data in 28 states over two years, 2014-2015. The sample includes 56 
observations.  
Table 1 
Label Variable Mean Std. 
Dev. 
Expected 
Sign 
Y Natural and semi-synthetic opioid overdose deaths 
excluding heroin per 100,000 persons 
5.05 3.59  
PSO Prescription sales of oxycodone per 100,000 
persons 
20.530 6.58 + 
PSH Prescription sales of hydrocodone per 100,000 
persons 
10.44 6.05 + 
UR Unemployment rate  0.06 0.01 Ambiguous 
SUI Firearm suicides per 100,000 persons 7.04 2.92 + 
PH Preventable hospitalizations per 100,000 persons 1359.7 283.19 + 
ED Percent of civilians who visited the emergency 
department during the past year 
0.0187 0.04 + 
BD Percent of adults binge drinking during the past 30 
days 
0.164 0.03 Ambiguous 
C Presences of legal medical or recreational cannabis 
legislation 
0.57 0.5 - 
F State public health funding per person 40.5 39.09 Ambiguous 
T State cigarette excise tax rate 1.78 1.12 Ambiguous 
YR Year of observation (2014 = 0, 2015 = 1) .5 .5 Ambiguous 
 
The initial specification of the empirical model is: 
(S1)     Y = β0 + β1 PSO + β2 PSH + β3 UR + β4 SUI + β5 PH + β6 ED + β7 BD + β8 C + β9 F + 
β10 T + β11 YR + ɛ 
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where Y equals the natural and semi-synthetic opioid overdose deaths excluding heroin per 
100,000 persons. 
 
Regression analysis was used to evaluate three model specifications of the model in 
Microsoft Excel.  The empirical results for all specifications are reported in Table 2.  The R-
squared value measures the proportion of the variation in the dependent variable (Y) explained 
by the independent variables for a linear regression model.  The adjusted R-squared adjusts the 
statistic based on the number of independent variables in the model.  The adjusted R2 for the 
initial model (S1) is 0.6427 which means that 64.27% of the Y is explained by the independent 
variables in the specification.  One variable, PSH, has a different sign than expected in the initial 
regression (S1) results. The F-test for a linear regression indicates whether any of the 
independent variables in a multiple linear regression model are jointly significant.  The F-test 
indicates that the variables are jointly significant at α= 0.001.  The t-tests indicate that PSO and F 
are significant at α= 0.01, SUI and ED are significant at α= 0.10, while all other variables are 
insignificant.  Tests for superfluous variables and omitted variables tests suggest that PSH and T 
are superfluous, and they were removed from the model.  
The second specification is: 
(S2)     Y = β0 + β1 PSO + β2 UR + β3 SUI + β4 PH + β5 ED + β6 BD + β7 C + β8 F + β9 YR + ɛ. 
The adjusted R2 increased only slightly from 0.6427 in specification (S1) to 0.6581 in 
specification (S2).  Multicollinearity is when one independent variable in a multiple regression 
model can be used to predict another independent variable.  Multicollinearity generally occurs 
between two or more independent variables that have a high correlation.  Their correlation 
creates redundant information in the model. Multicollinearity may produce overinflated standard 
errors, consequently, independent variables that should be statistically significant are found to be 
statistically insignificant. 
 47 
 
A test for multicollinearity indicates no serious collinearity between the independent 
variables. The variance inflation factor (VIF) quantifies the severity of multicollinearity in an 
ordinary least squares regression analysis and provides an index that measures how much an 
estimated regression coefficient is increased because of collinearity.  If the VIF value is above 5, 
multicollinearity may be problematic for that independent variable.  All of the VIF values are all 
below 4.   
Heteroskedasticity occurs when the variability of the error term varies with the 
independent variables.  The White test is a general approach which tests for the presence of 
heteroskedasticity in the model.  The White test indicates that heteroskedasticity is present at the 
5% level.  The Park test is used to test individual variables for heteroskedasticity.  The Park test 
for Preventable Hospitalizations (PH) indicates the presence of heteroskedasticity, therefore, PH 
was removed from the model.   
            The third specification of the model is: 
(S3)     Y = β0 + β1 PSO + β2 UR + β3 SUI + β4 ED + β5 BD + β6 C + β7 F + β8 YR + ɛ 
The adjusted R2 decreased in the third model specification but not significantly.  The 
final specification (S3) is consistent with theory.  Three variables are significant at α= .01 
(prescription sales of oxycodone per 100,000 persons, percent of civilians who visited an 
emergency department during the past year, and state public health funding per person), one 
variable is significant at α= 0.05 (firearm suicides per 100,000 persons), and one variable is 
significant at α= 0.10 (presences of legal medical or recreational cannabis legislation), and two 
variables (the unemployment rate and percent of adults binge drinking during the past 30 days) 
are insignificant.   
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Serial correlation is a potential problem for time-series data.  Serial correlation is the 
correlation of an observation with a delayed copy of itself as a function of delay.  The Durbin–
Watson statistic is a test statistic used to detect the presence of first order serial correlation when 
errors in one-time period are correlated with errors in the next time period.  The Durbin-Watson 
test suggests that serial correlation is not present in the final specification (S3). Tests for 
multicollinearity indicate no collinearity between the independent variables.  However, there is 
some heteroskedasticity with the model specification.  The heteroskedasticity is likely due to the 
limited number of observations and omitted variables reflecting the complexity of the opioid 
epidemic.  
In summary, the regression analysis based on state-level data is consistent with theory 
and prior empirical research.  The adjusted R2 is 0.6448; the final specification has an 
explanatory power of 64.48%.  Empirical results suggest that there is a highly significant positive 
association between natural and semi-synthetic opioid overdose deaths and prescription sales of 
oxycodone (α= 0.01).  These results are similar to prior empirical studies and highlight the 
important role that prescriber behavior plays in determining opioid overdose deaths.   
The empirical results also suggest the importance of user behavior and characteristics. 
Emergency department visits have a highly significant positive association with natural and 
semi-synthetic opioid overdose deaths (α= .01).  As mentioned earlier, frequent emergency 
department visits have been linked to nonmedical opioid use, drug diversion and poorly managed 
pain (Brady et al 2015). Firearm suicide rates are also significantly and positively correlated with 
opioid overdose deaths (α= .05), suggesting that mental health status is an important determinant 
in opioid overdose deaths.  This is consistent with research by Davis et al (2017) who find that 
having a mental health disorder significantly increases the likelihood or treating pain with 
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opioids. Although binge drinking is insignificant, it is negatively associated with opioid overdose 
deaths which implies opioids and alcohol may be substitute goods.  
 The importance of environmental and systemic factors is also supported by the results 
based on state level data. The presence of legal cannabis legislation has a significant negative 
association with opioid overdose deaths (α= .10).  These results suggest that cannabis and 
opioids may be substitutes, possibly because both drugs relieve pain. The unemployment rate is 
insignificant. This is consistent with some of the prior research that suggests that the weak 
relationship that exists between economic decline and drug mortality rates is mostly explained by 
confounding factors (Ruhm 2018).   
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Table 2 
State Level Results 
Dependent Variable: Y 
Independent 
Variables 
Coefficients 
(P-values) 
 (S1) (S2) (S3) 
PSO 0.1993*** 
(0.0100) 
0.2041*** 
(0.0023) 
0.2165*** 
(0.0015) 
PSH -0.0141 
(0.8931) 
__ __ 
UR 34.6347 
(0.4606) 
31.7127 
(0.4239) 
50.2381 
(0.1978) 
SUI 0.5316* 
(0.0850) 
0.5013*** 
(0.0053) 
0.2999** 
(0.0201) 
PH 0.0033 
(0.1757) 
0.0031* 
(0.0991) 
__ 
ED 19.7035* 
(0.0956) 
20.3075* 
(0.0540) 
29.0558*** 
(0.0023) 
BD 9.1051 
(0.6468) 
8.4535 
(0.6485) 
-0.2936 
(0.9871) 
C -0.0080 
(0.9941) 
-0.0298 
(0.9750) 
-1.1614* 
(0.0931) 
F 0.0410*** 
(0.0001) 
0.0405*** 
(0.00001) 
0.0379*** 
(0.00003) 
T 0.0027 
(0.9958) 
__ __ 
YR 0.0780 
(0.9061) 
0.0786 
(0.9030) 
0.2152 
(0.7415) 
Constant -15.9469* 
(0.0268) 
15.5188** 
(0.0137) 
-10.6586* 
(0.0554) 
Adjusted R2  0.6427 0.6581 0.6448 
***Significant at the 1% level 
**Significant at the 5% level 
*Significant at the 10% level 
   
B. County Level Analysis 
1. Data  
The second empirical model uses county level cross-sectional data for the year 2017 to 
examine factors related to opioid overdose deaths in the United States.  Observations from 
counties in Kentucky, Ohio, Pennsylvania, Virginia, and West Virginia are used in this analysis.  
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A total of 68 observations were used.  All the data for the independent variables in the model 
was obtained from the County Health Rankings & Roadmaps database.  Data for the dependent 
variable, opioid overdose deaths, was obtained from the CDC Wonder database.  
2. Model Specification and Regression Results 
As in the state level analysis, proxies for prescriber behavior, user behavior and 
characteristics, and environmental and systemic factors are used to explain overdose mortality in 
model specifications at the county level.  
The opioid prescribing rate per 100 persons (OPR) is included as a measure of prescriber 
behavior within a county. Opioid prescriptions increase access to opioids and make opioid 
addiction more likely. The opioid prescribing rate is expected to be positively associated with 
opioid overdose deaths (Paulozzi et al 2011b).   
Four variables are used as measures of user behavior and characteristics. The variables 
include the average number of physically unhealthy days reported by an individual per month 
(PUD), the percent of adults reporting frequent mental distress (FMD), binge drinking behavior 
measured as the percent of adults reporting excessive drinking (BD), and preventable hospital 
stays, calculated from discharges for ambulatory care sensitive conditions per 1,000 Medicare 
enrollees (PHS). 
Both the average number of physically unhealthy days reported by an individual per 
month and the percent of adults reporting frequent mental distress are expected to be positively 
associated with the opioid mortality rate. As the review of the literature suggests, physical and 
mental health status are factors that determine the dosage and rate of opioid prescribing. Having 
a mental disorder significantly increases the likelihood of treating pain with opioids (Davis et al 
2017).  
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Binge drinking behavior and preventable hospital stays are included as variables in both 
the state and county analysis. As discussed in the state level analysis, the overall relationship 
between binge drinking behavior and opioid overdose mortality is ambiguous, and preventable 
hospital stays are expected to be positively correlated with opioid overdose deaths.    
Five variables are used to measure environmental and systemic factors. The variables 
include the unemployment rate (UR), the percent of children in poverty (CP), the high school 
graduation rate (HS), the percent of uninsured adults (UI), and the number of primary care 
physicians per 100,000 persons (PCP).  
The unemployment rate is included as a variable in both the state and county analysis. As 
discussed in the state level analysis, the overall relationship between the unemployment rate and 
opioid overdose mortality is ambiguous.   The percentage of children in poverty is predicted to 
be positively associated with opioid overdose deaths as lower-income individuals are more likely 
to abuse opioids relative to the general population (Jones 2016). The percent of uninsured adults 
has an ambiguous association with opioid overdose deaths. Insurance provides access to 
addictive opioid prescriptions but uninsured individuals are associated with poverty which 
suggests a greater risk for opioid abuse (Chase 2019, Orgera and Tolbert 2019, Jones 2016). 
High school graduation rates are expected to be negatively correlated with opioid overdose 
deaths (independent of income) as more educated individuals are produce health more 
efficiently. For example, more educated individuals have a greater ability to understand the 
negative consequences of unhealthy behaviors (Grossman 1972). The net effect of the number of 
primary care physicians per 100,000 persons on opioid overdose mortality is uncertain. Although 
an increase in primary care physicians may increase access to health care and the opportunity for 
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more effective treatments for addiction, an increase in physicians may also be associated with an 
increase in opioid prescriptions to treat pain.  
An explanation of the variables and descriptive statistics is in Table 3. Descriptive 
statistics are based on data from 68 counties in 2017. The sample includes 68 observations.  
Table 3 
Label Variable Mean Std. 
Dev. 
Expected 
Sign 
Y Crude rate of accidental poisoning by and exposure 
to narcotics and psychodysleptics [hallucinogens] 
24.484 15.672  
FMD Percent of adults reporting frequent mental distress 11.537 1.361 + 
BD Percent of adults reporting excessive drinking 17.431 2.256 Ambiguous 
UR Unemployment Rate 5.014 0.951 Ambiguous 
OPR Opioid Prescribing Rate per 100 persons 63.791 16.692 + 
CP Percent of Children in Poverty 19.506 7.866 + 
HS High School Graduation Rate 84.475 8.292 - 
PCP Primary care physicians per 100,000 persons 79.589 25.922 Ambiguous 
PUD Average number of reported physically unhealthy 
days per month 
3.670 0.546 + 
PHS Preventable hospital stays; discharges for 
ambulatory care sensitive conditions/Medicare 
enrollees * 1,000 
54.142 12.053 + 
UI Percent of adult population uninsured 10.197 2.227 Ambiguous 
 
The initial specification of the model is:  
(C1) Y = β0 + β1 FMD + β2 BD + β3 UR + β4 UR + β5 OPR + β6 CP + β7 HS + β8 PCP + β9 PUD + β10 
PHS + β11 UI + ɛ 
where Y = the crude rate of accidental poisoning by and exposure to narcotics and 
psychodysleptics [hallucinogens].8 
 
 
Regression analysis was used to evaluate three model specifications of the model in 
Microsoft Excel.  The empirical results for all specifications are reported in Table 4. The signs 
 
8 I was unable to find strictly opioid overdose deaths for the county data.  However, opioids contribute to the 
majority of the deaths caused by accidental poisoning by and exposure to narcotics and psychodysleptics 
[hallucinogens]. 
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on all variables in the initial model specification (C1) are consistent with predictions with the 
exception of the rate of high school graduates. The F-test indicates that the variables are jointly 
significant at α= 0.001.  The t-tests indicate that one variable, the unemployment rate (UR), is 
significant at α= 0.01.  Tests for superfluous variables and omitted variables suggest that FMD is 
superfluous, and it was removed from the model.   
The second specification is: 
(C2)     Y = β0 + β1 BD + β2 UR + β3 UR + β4 OPR + β5 CP + β6 HS + β7 PCP + β8 PUD + β9 PHS 
+ β10 UI + ɛ  
There is almost no change in the adjusted R2 in the second model specification (0.4515 in 
the first specification and 0.4586 in the second specification).  Even though the high school 
graduation rate is insignificant, the sign remains positive. Multicollinearity tests indicate 
potential collinearity problems with two variables, CP and PUD as their VIF values exceeded 5.  
When the variable, CP was removed from the model, the VIF values for the all remaining 
variables were below 5.  The White test indicates that impure heteroskedasticity is present in this 
specification of the model.  The Weighted Least Squares (WLS) is a method used to remove 
heteroscedasticity. WLS incorporates weights associated with each data point. The size of the 
weight indicates the precision of the information contained in the associated observation.  All of 
the variables are rates or percentages and WLS did not yield improved results in the third 
specification.  The variable, PHS was removed to reduce the heteroscedasticity. 
The third specification of the model is: 
(C3) Y = β0 + β1 BD + β2 UR + β3 OPR + β4 HS + β5 PCP + β6 PUD + β7 UI + ɛ 
Once again, the adjusted R2 did not change significantly. The signs of all variables in the 
final specification (C3) is consistent with those that were hypothesized. Two variables are 
significant at α= 0.01 (Unemployment Rate, UR and Physically Unhealthy Days, PUD), one 
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variable is significant at α= 0.05 (Opioid Prescribing Rate, OPR), and the remaining four 
variables (Binge Drinking, BD; High School Graduation, HS; Primary Care Physicians, PCP, 
and Uninsured, UI) are insignificant.  Serial correlation is often not present in cross-sectional 
data, and correlation tests indicated there were no problems with correlation.  The White test 
indicates that impure heteroskedasticity is present in this specification of the model; however, the 
heteroskedasticity was less of problem for the final specification (C3) than the previous 
specification (C2).  All of the variables are rates or percentages, so it is not surprising that WLS 
did not yield improved results in the third specification (C3). The impure heteroskedasticity is 
likely due to the limited number of observations and omitted variables reflecting the complexity 
of the opioid epidemic. 
In summary, the regression analysis based on county level data is consistent with theory 
and prior empirical research.  The adjusted R2 is 0.4448; the final model has an explanatory 
power of 44.48%. The results suggest that opioid prescription rates have a significant and 
positive correlation with opioid overdose deaths (α= 0.05).  This result is consistent with the 
analysis at the state level and with prior empirical studies. It provides additional evidence that 
prescriber behavior plays an important role in determining opioid overdose deaths.   
The empirical results also suggest the importance of user behavior and characteristics. 
There is a strong significant positive association between opioid overdose deaths and physically 
unhealthy days (α= 0.01). Individuals who are physically unhealthy are more likely to suffer 
from chronic pain or high impact chronic pain and to be treated with opioids.  The impact of 
chronic pain is associated with restrictions in daily activities while high impact chronic pain is 
debilitating, leading to major limitations in work, social, recreational, and self-care activities 
(CDC 2018). Theoretically, the relationship between binge drinking and opioid deaths is 
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ambiguous, depending on whether alcohol and opioids are substitutes or complements.  In both 
the state and county analysis, binge or excessive drinking is negatively correlated with opioid 
overdose deaths.  Even though the relationship is insignificant, this may imply that alcohol and 
opioids are weak substitutes.   
 The importance of environmental and systemic factors is also supported by the results 
based on county level data. The empirical results at the county level suggest a highly significant 
negative association between opioid overdose deaths and the unemployment rate (α= 0.01).  
Although this result differs from the insignificant positive association with unemployment found 
in the analysis based on state level data, the empirical literature on the relationship of 
unemployment and opioid abuse is mixed. Harris et al (2019) find a significant negative effect 
between opioid prescriptions and the unemployment rate. Other empirical studies imply a weak 
relationship between economic decline and drug mortality rates which is mostly explained by 
confounding factors (Ruhm 2018).  Finally, Currie et al (2018a) suggest that no simple causal 
relationship exists between economics conditions and opioid abuse. The final variable used to 
measure environmental and systemic factors, high school graduation rates, has an insignificant 
negative association with opioid overdose morality.  These results, while insignificant, imply 
education and an increase in economic opportunity is a deterrent to opioid overdose deaths.    
Primary care physician per 100,000 persons and the uninsured population were also 
included in the regression model to capture environmental and systemic factors. Both variables 
have insignificant negative associations with opioid overdose morality. In theory, greater access 
to medical care either because there are more physicians available to treat patients or because 
there are more insured individuals who can afford care, has an ambiguous relationship to opioid 
mortality. Prescriber behavior varies widely among physicians and as the number of physicians 
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and the number of insured patients increase, this may provide greater access to opioid 
prescriptions. On the other hand, an increase in physicians and insured individuals may provide 
access to better and more effective pain management leading to fewer opioid prescriptions. 
These results suggest that more physicians are associated with fewer prescriptions. New 
guidelines for prescribing practices and managing pain have been implemented in recent years 
leading to a decline in opioid prescribing rates. The county level results also suggest that an 
increase in the rate of uninsured individuals leads to a decrease in opioid overdose deaths which 
may suggest that greater access to medical care leads to more opioid prescriptions for pain. 
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Table 4 
County Level Results 
Dependent Variable: Y 
Independent 
Variables 
Coefficients 
(P-values) 
 (C1) (C2) (C3) 
FMD 2.3615 
(0.7989) 
__ __ 
BD 2.3615 
(0.6209) 
-1.7659* 
(.0886) 
-1.0264 
(0.2680) 
UR -9.4963*** 
(0.0011) 
-9.6217*** 
(0.0008) 
-7.3811*** 
(0.0027) 
OPR 0.1855 
(0.1551) 
0.1800 
(0.1631) 
0.2429* 
(0.0523) 
CP 0.6733 
(0.2735) 
0.8263 
(0.1189) 
__ 
HS 0.1656 
(0.4900) 
0.1471 
(0.5318) 
-0.0300 
(0.8857) 
PCP -0.0140 
(0.8236) 
-0.0134 
(0.8297) 
-0.0024 
(0.9698) 
PUD 7.5456 
(0.5011) 
12.0032 
(0.5014) 
17.9789*** 
(0.0017) 
PHS 0.1063 
(0.6478) 
0.0852 
(0.7074) 
__ 
UI -1.1012 
(0.3710) 
-1.3321 
(0.2400) 
-0.2866 
(0.7562) 
Constant 13.8110 
(0.7989) 
29.4623 
(0.5014) 
1.8438 
(0.9628) 
Adjusted R2 0.4515 0.4586 0.4448 
***Significant at the 1% level 
**Significant at the 5% level 
*Significant at the 10% level 
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V. Conclusions 
Over the last two decades, the opioid epidemic has led to serious negative consequences.  
Opioid addiction adversely affects an individual’s mental and physical health.  In addition, the 
societal and economic costs are substantial.  Opioid addiction is associated with an increase in 
other diseases such as hepatitis, domestic and child abuse, crime, lost wages and employment.  
Although the causes of the opioid crisis were multifaceted, primary factors were an increased 
demand for pain treatment, two widely cited notes based on observations of patients suffering 
from acute and chronic pain which underestimated opioid addiction risk, the recognition of pain 
as a vital sign, and aggressive pharmaceutical marketing for opioid prescriptions.   
This study investigates the risk factors that are associated with opioid addiction. The 
opioid overdose mortality rate is used as a measure of the seriousness of the opioid epidemic. 
Theoretical concepts from Grossman’s production function of heath (1972) and Becker and 
Murphy’s model of rational addiction (1988) are used to develop empirical models that explore 
the relationship between risk factors and opioid overdose deaths.   
The production function of health summarizes the relationship between health inputs 
such as medical care and lifestyle and health outcomes such as life expectancy.  Medical services 
and the time devoted to the production of health impact an individual’s health.  Depreciation in 
health is related to age and behavioral factors such as alcohol consumption, smoking, and 
obesity.  Addiction to substances such as opioids also leads to a deterioration in health stock.  
Becker and Murphy developed a model in which individuals rationally choose to consume 
addictive goods.  Their model implies that addiction is more likely in individuals who discount 
the future heavily, that is, these individuals focus less on the future effects from current 
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consumption choices.  Their model also implies that individuals respond to price increases in 
specific addictive substances by consuming cheaper substitute goods.  
More broadly, Grossman’s model of health suggests that health outcomes are affected by 
a variety of health factors which include clinical care, health behaviors, social and economic 
factors, and environmental characteristics. Clinical care includes both access to care and quality 
of care. Health behaviors include decisions about diet, exercise, and use of cigarettes, alcohol, 
and drugs. Social and economic factors include employment, income, education, family, social 
support, and community safety. Characteristics of the physical environmental include housing 
and transit.  Following King et al (2014), health factors that affect the opioid mortality rate are 
grouped into three broad categories: prescriber behavior, user behavior and characteristics, and 
environmental and systemic factors.  
The empirical analysis examines the relationship between risk factors that are associated 
with prescriber behavior, user behavior and characteristics, environmental and systemic factors 
and opioid overdose mortality. Two regression models are used to analyze data at the state and 
county level. The state level analysis is based on panel data. The county level analysis is based 
on cross-sectional data. 
The behavior of prescribers may increase the risk associated with opioid overdose deaths 
in several ways and it has been shown to play a key role in opioid-related overdose deaths. Three 
measures of prescriber behavior are initially included in this study: prescriptions sales of 
oxycodone and hydrocodone at the state level and opioid prescribing rates at the county level. 
Prescription sales of hydrocodone was dropped from the empirical model after tests indicated 
that it was superfluous. Both analyses at the state and the county level indicate that there is a 
significant positive association between prescriber behavior and opioid overdose mortality. The 
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empirical results at the state level indicate that an increase in the prescription sales of oxycodone 
are statistically associated with an increase in natural and semi-synthetic opioid overdose deaths 
at the 1% level. Similarly, the analysis at the county level suggests that an increase in opioid 
prescription rates is positively correlated with the crude rate of accidental poisoning by narcotics 
and psychodysleptics at the 5% level. While the latter measure of opioid overdose mortality 
includes substances that are not opioids, opioids make up the majority of those substances. These 
results highlight the important role that prescriber behavior plays in determining opioid overdose 
deaths and in contributing to the opioid epidemic. The results are consistent with many empirical 
studies described in the literature review and are also consistent with the historical events 
described in the introduction, where aggressive pharmaceutical marketing of opioids is linked to 
the opioid epidemic. 
The behavior of users and user characteristics may also increase the risk associated with 
opioid overdose deaths. Variables used to measure user behavior and characteristics in the state 
level analysis include preventable hospitalizations, emergency department visits, binge drinking, 
and firearm suicides.  Variables used to measure user behavior and characteristics in the county 
level analysis include preventable hospitalizations, binge drinking, frequent mental distress, and 
physically unhealthy days.  
Both the empirical analysis at the state and county level result in a final specification in 
which preventable hospital stays are removed due to the presence of heteroskedasticity. 
However, emergency room visits are statistically associated with opioid overdose mortality at the 
1% level in the state level analysis. This is consistent with prior studies which find a strong 
association between the rate of emergency department visits and an increased risk for overdoses 
from prescription drugs (Brady et al 2015). 
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Although binge drinking behavior is included in both empirical models, it is insignificant. 
Theoretically, the overall relationship between binge drinking and opioid overdose mortality is 
ambiguous, and depends on whether alcohol and opioids are substitutes or complements. While 
not significant in either model, an increase in binge drinking suggests a decline in the opioid 
overdose mortality rate which implies that alcohol and opioids may be substitutes. However, the 
empirical results are mixed and some researchers find evidence of a complementary relationship 
(Esser et al (2019). 
As with preventable hospitalizations, firearm suicides are associated with mental 
disorders, chronic pain, and substance abuse (Meiman et al 2015; Ilgen et al 2016; Martin 2018). 
Consistent with these findings, firearm suicide rates are positively correlated with opioid 
overdose deaths at a 5% level of significance in the state level analysis. Both physical and mental 
health status are factors that determine the dosage and rate of opioid prescribing. The presence of 
a mental disorder significantly increases the likelihood of treating pain with opioids (Davis et al 
2017).  The county level analysis suggests that an increase in physically unhealthy days is 
associated with an increase in opioid overdose mortality at the 1% significance level.   Although 
frequent mental distress was initially included in the county level analysis, it was removed from 
the final specification because tests suggested that it was a superfluous variable.   
The final broad category of health factors that affect the opioid mortality are 
environmental and systemic factors. Variables used to measure environmental and systemic 
factors in the state level analysis include the unemployment rate, per capita state public health 
funding, the state excise tax on cigarettes, and the existence of medical or recreational cannabis 
legislation. Variables used to measure environmental and systemic factors in the county level 
analysis include the unemployment rate, the percent of children in poverty, the high school 
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graduation rate, the percent of uninsured adults, and the number of primary care physicians per 
100,000 persons.  
 The unemployment rate is included in both the state and county analysis. The effect of 
the unemployment rate on opioid overdose deaths is ambiguous.  Theoretically, as the 
unemployment rate increases and economic conditions decline, an increase in opioid abuse and 
overdoses would be expected. However, evidence on the relationship between the unemployment 
rate and the opioid overdose rate is mixed.  In addition, some studies find evidence of reverse 
causality between these two variables, that is, opioid abuse has a negative impact on the 
unemployment rate (Harris 2019). Although the unemployment rate is positively associated with 
opioid overdose mortality in the state analysis, it is insignificant. The empirical results at the 
county level suggest that the unemployment rate is negatively correlated with opioid overdose 
deaths and is statistically significant at the 1% level. 
The net effect of state public health funding per person on opioid overdose deaths is 
ambiguous. While state public health public funding can be used to increase measures to combat 
the opioid epidemic, public health funding also increases access to health care and pain 
prescriptions such as opioids. Public per capita health funding is positively related to opioid 
overdose deaths and significant at the 1% level in the state level analysis.  This suggests that an 
increase in public health funds may have an overall effect of increasing access to opioids.  
Cigarettes and cannabis are alternative addictive goods. In theory, the impact of the state 
excise tax on cigarettes on the opioid overdose death rate is ambiguous, depending on whether 
cigarettes serve as a substitute or a complement to opioid use. Cigarette excise taxes were 
included in the state level analysis, however, this variable was removed from the model after test 
indicated that it was superfluous. Opioid overdose deaths have been driven by prescriptions to 
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treat chronic pain. Because medical cannabis is used to treat pain, states in which medical 
cannabis is legal may have lower rates of opioid abuse and overdose deaths. The presence of 
cannabis legislation is significant at the 10% level and is negatively associated with opioid 
overdose deaths in the state level analysis. These results suggest that cannabis and opioids are 
substitutes, which is consistent with the empirical findings in Bachhuber et al (2014) and 
(Chihun and Li et al (2019).  
The final environmental and systemic risk factors are measures at the county level. These 
measures include the percent of children in poverty, the high school graduation rate, the percent 
of uninsured adults, and the number of primary care physicians per 100,000 persons. The 
percentage of children in poverty was removed from the model after tests indicated significant 
multicollinearity. The percent of uninsured adults has an ambiguous association with opioid 
overdose deaths. Insurance provides access to addictive opioid prescriptions but uninsured 
individuals are associated with poverty which suggests a greater risk for opioid abuse (Chase 
2019, Orgera and Tolbert 2019, Jones 2016). Although the uninsurance rate is insignificant, it is 
negatively associated with opioid overdose mortality, suggesting that more access to medical 
care provides more access to opioid prescriptions. High school graduation rates are expected to 
be negatively correlated with opioid overdose deaths (independent of income) as more educated 
individuals are produce health more efficiently. For example, more educated individuals have a 
greater ability to understand the negative consequences of unhealthy behaviors (Grossman 1972).  
High school graduation rates have an insignificant negative association with opioid overdose 
morality.  Although these results, are insignificant, the negative association implies that 
education and an increase in economic opportunity is a deterrent to opioid overdose deaths.    
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The net effect of the number of primary care physicians per 100,000 persons on opioid 
overdose mortality is uncertain. Although an increase in primary care physicians may increase 
access to health care and the opportunity for more effective treatments for addiction, an increase 
in physicians may also be associated with an increase in opioid prescriptions to treat pain. The 
statistical relationship between primary care physicians and the opioid overdose mortality rate is 
insignificant but negative, which suggests that more physicians are associated with fewer 
prescriptions. This result may be due, in part, to prescribing guidelines. New guidelines for 
prescribing practices and managing pain have been implemented in recent years leading to a 
decline in opioid prescribing rates.  
A major theme of this paper is that understanding the opioid epidemic is complex. The 
empirical results at the state and county level suggest that there are many risk factors associated 
with opioid overdose mortality. Additionally, the opioid crisis has not impacted the nation in a 
uniform way. In particular, some communities, such as counties in Kentucky, Ohio, West 
Virginia, and Pennsylvania have been impacted much more severely than others. Finally, the 
opioid drug problem has evolved in different ways over time for specific communities. Some 
counties and states now have severe problems with heroin and fentanyl. As many empirical 
researchers have suggested, more studies at the community level are needed as many factors 
contribute to the institutional environment faced by different regions of the country. The 
complexity of the opioid epidemic is consistent with Grossman’s model of health in which health 
outcomes are affected by a variety of health factors which include clinical care, health behaviors, 
social and economic factors, and environmental characteristics.  
An implication of this analysis and similar empirical studies is that addressing the opioid 
epidemic requires multifaceted and targeted solutions in order to effectively and efficiently 
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allocate resources. Additionally, developing effective policy solutions in addition to treatment 
options for opioid addiction requires an interdisciplinary approach.  As discussed earlier, the 
range of relevant knowledge includes the biological/chemical and non-biological causes of 
addiction, pain prevalence and its management, the historical events leading to the role of 
opioids in treating pain, and knowledge about the epidemic from empirical studies based on 
analyses at several levels including individuals, communities, and states.  The results of 
empirical studies focused on the opioid epidemic can guide legislators as they propose policies to 
reduce and treat opioid addiction or addiction to other substances.  
In particular, this study suggests that opioid prescriptions (prescriber behavior), mental 
and physical health and emergency department visits (user behavior and characteristics), and 
cannabis legislation (environmental and systemic factors) are all important risk factors in opioid 
overdose deaths. These findings have several implications. First, solutions to combat the opioid 
epidemic will involve balancing the need to effectively manage chronic pain while preventing 
opioid addiction and abuse. Second, effective solutions will involve multiple strategies which 
restrict the supply and reduce the demand for opioids. The strong association between opioid 
prescriptions and opioid overdose mortality implies that strategies to restrict the legal access of 
opioids, such as preventing drug diversion, prescription drug monitoring programs, provider 
education, and prescribing guidelines might be effective. Strategies to reduce the demand for 
opioids may include educating patients about the dangers of opioid use. In addition, increasing 
access to treatment for addiction disorders and access to medical care for individuals with mental 
and physical impairment may reduce opioid use. Finally, reducing the harmful consequences 
associated with opioid addiction by increasing the availability of naloxone to reverse overdoses 
or increasing buprenorphine to reduce withdrawal symptoms would be helpful. Policies that 
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regulate substances that serve as opioid substitutes may also be useful in reducing opioid abuse. 
The results from the state level analysis suggest that policies that legalize cannabis may be 
helpful in reducing opioid overdose deaths.  Overall, the results of this paper support the need for 
the development of public health policies which are designed on the basis of empirical 
information. Targeting strategies to specific local needs can more effectively improve both the 
health of individuals and the economic and societal well-being of communities. 
In conclusion, this study suggests the need for future research. While my empirical 
results were consistent with much of the previous literature, there are ways in which my study 
could be improved and expanded.  As more data becomes available, incorporating additional 
variables, observations, and modeling techniques could improve the ability of the model to 
predict opioid overdose deaths. For example, I initially planned to examine the impact of state 
laws passed to limit prescription opioids (PDMPs) on opioid overdose mortality. As discussed in 
the review of the literature, some research suggests that PDMPS are not significant in reducing 
opioid overdose deaths. However, state laws regarding drug monitoring programs differ. Some 
state laws simply make information on prior opioid prescriptions received by patients available 
to physicians while other states require physicians to look at prior opioid prescriptions received 
by their patients. Programs that require physicians to examine prior opioid prescriptions given to 
their patients are significantly related to a reduction in opioid overdose deaths. As I collected 
data on PDMPS, I realized that including this variable would require access to a more detailed 
dataset. Although all states except one have passed drug monitoring programs, the laws vary not 
only by whether the physician is required to look at the patient history of drug prescriptions, but 
also by the specific type of prescription monitored and by the type of physician specialist 
required to access the patient history. I had also planned to examine the impact of a county 
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legislation on alcohol sales explore whether a county was dry or wet had an impact on opioid 
overdose mortality. However, almost all of the counties in the data set where wet.  Furthermore, 
the ability to access and use data at the individual level would be helpful in examining the impact 
of demographic characteristics on the risk for opioid overdose deaths. Finally, using a more 
complicated time-series cross-sectional modeling approach could improve both the state and 
county level analysis.   
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